[STUDY_ID_REMOVED]  
 
Study ID: CGP‐MD‐01 
 
Title:  A PHASE 2/3, MULTICENTER, RANDOM IZED, DOUBLE-BLIND, PLACEBO 
CONTROLLED, PARALLEL-GR OUP STUDY TO EVALUATE THE EFFICACY, 
SAFETY, AND TOLERABILITY OF MULTIP LE DOSING REGIMENS OF ORAL AGN-
241689 IN EPISODIC MIGRAINE PREVENTION 
 
 
Protocol Amendment  2 Date: 11 Sept 2017 
Allergan Confidential Protocol CGP -MD-01, Amendment 2
1Title Page
ALLERGAN – CONFIDENTIAL
The following contains confidential, proprietary  information 
which is the propert y of Allergan
A PHASE 2/3, MUL TICENTER, RANDOMIZED, DOUBLE -BLIND, PLACEBO -
CONTROLLED , PARALLEL -GROUPSTUDY TO EVALUATE THE EFFI CACY, 
SAFETY, AND TOLERABILITY  OF MUL TIPLE DOSING REGIMENS OF ORAL  
AGN-241689 IN EPI SODIC MIGRAINE PREVENTION
Protocol Number:  CGP-MD-01, Amendment 2
Phase: 2/3
Name of Investigational Product: AGN-241689
Sponsor:
US Agent:Allergan Pharmaceuticals International Limited
Clonshaugh Industrial Estate, Coolock, Dublin 
17, Ireland
Allergan ( Sales, LLC )
2525 DuPont Drive
Irvine, California USA
92612
Emergency Telephone Number(s):
Serious Adverse Event Reporting 
Fax Number(s):
Allergan Medical Monitor
Contact Information:Refer to the Study Contacts Page
Allergan Signatory:
Original Protocol Date:
Protocol Amendment 1 Date :
Protocol Amendment 2 Date:09 May 2016
11Nov2016
11 Sep2017

Allergan Confidential Protocol CGP -MD-01, Amendment 2
2The following infor mation can be found on FDA  Form 1572 and/or study  contacts p age:  
Name and contact information of Allergan stud y personnel and Emergency  Telephone 
Numbers; name, address, and statement of qualifications of each investigator; name of each 
subinvestigator working under the supervision of the investigator; name and address of the 
research facilities to be used; name and address of each reviewing IRB; US 21 CFR 312.23 
section 6(iii)b .
Allergan Confidential Protocol CGP -MD-01, Amendment 2
3INVESTIGA TOR SIGNA TURE PAGE
INVESTIGATOR:
I agree to:
Implement and conduct this study  diligently and in strict compliance with the protocol, 
good clinical practices and all applicable laws and regulations.
Maintain all information supplied by  Allergan in confidence and, when this information 
is submitted to an I nstitution al Review Board (IRB), Independent Ethics Committee 
(IEC) or another group, it will be submitted with a designation that the material is 
confidential.
Ensure that all persons assisting with the trial are adequatel y informed about the protocol, 
the investig ational product(s), and their trial- related duties and functions.
I have read this protocol in its entirety  and I agree to all aspects.
Investigator Printed Name Signature Date
Allergan Confidential Protocol CGP -MD-01, Amendment 2
4Table of Contents
Title Page..................................................................................................................................1
Table of Contents ......................................................................................................................4
Protocol Summary ....................................................................................................................8
1.Background and Clinical Rationale .................................................................................16
1.1Background ............................................................................................................16
1.2Overview of AGN-241689................................
.....................................................16
1.3Rationale For Doses and Dose Regimens Selected ................................ ................18
2.Study Objectives and Clinical Hy potheses......................................................................18
2.1Study Objectives ....................................................................................................18
2.2Clinical Hy potheses...............................................................................................18
3. Study Design................................................................
....................................................19
3.1Structure .................................................................................................................19
3.2Efficacy Assessments.............................................................................................
19
3.5Data Safet y Monitoring Board ...............................................................................20
3.6Adjudication Committee ........................................................................................21
4.Study Population and Entry  Criteria................................................................................21
4.1Number of Patients .................................................................................................21
4.2Inclusion Criteria................................................................
....................................21
4.3Exclusion Criteria ...................................................................................................22
4.4Permissible and Prohibited Medications/T reatments .............................................25
4.4.1 Permissible Medications/T reatments ..........................................................25
4.4.2Prohibited Medications/T reatments ............................................................
26
4.4.3Definition of Females of (Non -)Childbearing Potential and/or Acceptable 
Contraceptive Methods ..............................................................................27
4.4.4Special Diet or Activities ............................................................................27
5.Study Treatments ................................ ................................ ................................ .............28
5.1Study Treatments and Formulations ................................ ................................ ......28
5.2Control Treatment(s) ................................ ................................ ..............................28
5.3Methods for Masking/Blinding ..............................................................................28

Allergan Confidential Protocol CGP -MD-01, Amendment 2
55.4Treatment Allocation Ratio and Stratification .......................................................28
5.5Method for Assignment to Treatment Groups/Randomization ..............................28
5.6Treatment Regimen and Dosing .............................................................................
29
5.7 Storage of Investigational products/T reatments .....................................................30
6.Response Measures and Summary
 of Data Collection Methods .....................................30
6.1Efficacy Measures ................................
..................................................................30
6.3Future Biomedical Research ..................................................................................34
6.4Safety Measures .....................................................................................................35
6.4.1Adverse Events ...........................................................................................35
6.4.2Events of Clinical I nterest..........................................................................35
6.4.3Clinical L aboratory  Determinations ...........................................................35
6.4.4Vital Signs..................................................................................................36
6.4.5Physical Examination .................................................................................37
6.4.6Electrocardiograms .....................................................................................37
6.4.7Columbia -Suicide Severity  Rating Scale (C -SSRS)..................................37
6.5Other Study  Supplies .............................................................................................38
6.6Summary  of Methods of Data Collection ..............................................................38
7.Statistical Procedures .......................................................................................................38
7.1Analysis Populations ..............................................................................................38
7.2Collection and Derivation of Primary  and Secondary  Efficacy Assessments........39
7.2.1Primary Efficacy Variable..........................................................................
40
7.2.2Secondary  Efficacy Variables.....................................................................
40
7.3Hypothesis and Methods of Analysis.....................................................................41
7.3.1Primary Efficacy Analyses.........................................................................41
7.3.2Secondary  Efficacy Analyses................................ ................................ .....42
7.6Subgroup Analyses................................ ................................ ................................ .44
7.7Sample Size Calculation ................................ ................................ ........................44
7.8Interim Analyses.....................................................................................................44

Allergan Confidential Protocol CGP -MD-01, Amendment 2
68.Study Visit Schedule and Procedures ..............................................................................45
8.1Patient Entry  Procedures ........................................................................................45
8.1.1Overview of Entry  Procedures ...................................................................45
8.1.2Informed Consent and Patient Privacy .......................................................45
8.2Washout Intervals...................................................................................................45
8.3Procedures for Final Study  Entry...........................................................................45
8.4
8.5Instructions for the Patients ....................................................................................50
8.6Unscheduled V isits.................................................................................................51
8.7 Compliance with Protocol................................
......................................................51
8.8Early Discontinuation of Patients ..........................................................................51
8.9Withdrawal Criteria ................................................................................................52
8.10Withdrawal from Future Biomedical Research ......................................................52
8.11Study Termination ................................................................
..................................52
9.Adverse Events ................................................................................................................52
9.1 Definitions................................
..............................................................................53
9.1.1Adverse Event ............................................................................................53
9.1.2Serious Adverse Event ................................................................................53
9.1.3Severity.......................................................................................................54
9.1.4Relationship to Study  Drug or Stud y Procedure ........................................54
9.2 Procedures for Reporting Adverse Events .............................................................54
9.3
Procedures for Reporting a Serious Adverse Event ...............................................54
9.4Exposure to I nvestigational Product du
ring Pregnancy ................................ .........55
9.5ALT or AST Elevations ..........................................................................................56
9.5.1Potential Hy ’s Law Cases ...........................................................................57
9.6Procedures for Unmasking of Investigational Product ................................ ..........58
10.Administrative I tems................................ ................................ ................................ .......58
10.1Protection of Human Patients.................................................................................58
10.1.1Compliance with I nformed Consent Regulations (US 21 CFR Part 50) and 
Relevant Country  Regulations ................................ ................................ ...58
10.1.2Compliance W ith IRB or IEC Regulations ................................................59

Allergan Confidential Protocol CGP -MD-01, Amendment 2
710.1.3Compliance W ith Good Clinical Practice..................................................59
10.1.4Compliance W ith Electronic Records; Electronic Signatures Regulations 
(US 21CFR Part 1 1)...................................................................................59
10.2Changes to the Protocol ................................ ................................ .........................59
10.3Patient Confidentiality ................................ ................................ ...........................59
10.3.1Patient Privacy ................................ ................................ ............................59
10.4 Documentation ................................ ................................ ................................ .......60
10.4.1Source Documents ................................ ................................ ......................60
10.4.2Case Report Form Completion ................................ ................................ ...61
10.4.3Study Summary ................................ ................................ ..........................61
10.4.4Retention of Documentation ................................ ................................ ......61
10.5Labeling, Packaging, and Return or Disposal of Investigational 
Products/T reatments ................................ ................................ ...............................62
10.5.1Labeling/Packaging ................................ ................................ ....................62
10.5.2Clinical Supply  Inventory ................................ ................................ ..........62
10.5.3Return or Disposal of Investigational Products/T reatments and/or Supplies
................................ ................................ ................................ ....................62
10.6Monitoring b y the Sponsor ................................ ................................ .....................62
10.7Handling of Biological Specimens ................................ ................................ ........63
10.8Publications ................................ ................................ ................................ ............63
10.9 Coordinating Investigator................................ ................................ .......................63
11.References ................................ ................................ ................................ ........................64
12.Attachments ................................ ................................ ................................ .....................66
12.1Examination Procedures, T ests, Equipment, and T echniques ................................66
12.1.1 International Classification of Headache Disorders, 3rdEdition, Beta 
Version .......................................................................................................66
12.2Examples of Prohibited Medications ................................ ................................ .....81
12.3Classification of Migraine Preventive Medications ................................ ...............83
12.4Glossary of Abbreviations ................................ ................................ ......................84
12.5Protocol Amendment 1 Summary ................................ ................................ ..........85
12.6Protocol Amendment 2 Summary ................................ ................................ ..........91
Allergan Confidential Protocol CGP -MD-01, Amendment 2
8Protocol Sum mary
Study Compound(s):   AGN-241689
Phase:  2/3
Study Objective(s): 
To evaluate the safety andtolerability of the following doses and dose regimens of AGN-241689 (10 -mg once 
daily [QD], 30-mg QD, 30 -mg twice daily [ BID], 60-mgQD,and 60-mg BIDforthe prevention of episodic 
migraine.
To characterize the dose/response relationship across the follow ing doses and dose regimens (10-mg QD, 
30-mg QD, 30 -mg BID, 60 -mg QD, and 60 -mg BID) for the prevention of episodic migraine.
To prospectively test for superiority of the following doses and dose regimens of AGN -241689 (10 -mg QD, 
30-mg QD, 30 -mg BID, 60 -mg QD, and 60 -mg BID) versus placebo for the prevention of episodic migraine in 
thispivotal trial.
Clinical Hypotheses:  In individuals with episodic m igraine, at least one active treatment arm, 60 mg QD or 60 
mg BID is superior to placebo as measured by the change from baseline in meanmonthly migraine/probable 
migraine (MPM) headache days across the 12-week treatment period .
AGN-241689has an acceptable safety and tolerability profile in patients with episodic migraine.
Study Design
Structure:  Multicenter, randomized, double -blind, placebo -controlled, parallel -group study
Duration:  The study will consist of a 4 week screening and base line period, a 12-week double -blind treatment 
period, and a safety follow-up period of 4additional weeks, for a total duration of 20 w eeks
Test Product : AGN-24168910-mg tablets , AGN-24168930-mg tablets , AGN-24168960- mg tablets . 
Investigational product will be over -encapsulated to maintain the blind.
Control:  AGN-241689placebotablets. Placebo tablets w ill be over -encapsulated to maintain the blind.
Dosage/Dose Regimen :  10-mg AGN-241689 QD, 30-mg AGN-241689QD, 60-mg AGN-241689QD, 30-mg 
AGN-241689BID, and 60-mg AGN-241689BID will be administered for 12 weeks duration
Randomization/Stratification :  Patients will be randomized to the following 6 arms  in a 2:1:2: 1:2:1 ratio:
Placebo (n =180)
AGN-241689 10- mgQD (n=90)
AGN-241689 30- mg QD (n=180)
AGN-241689 30- mg BID (n=90)
AGN-241689 60- mg QD (n=180)
AGN-241689 60- mg BID  (n=90)
To maintain the blind, investigational product will beover-encapsulated and administered orally for 12 weeks to 
all patients. Patients, therefore, w ill receive eith er placebo twice daily, a morning dose of AGN-241689with an 
evening dose of placebo, or AGN -241689twice daily.  
No stratification will be performed.
Visit Schedule :  Individual patient participation will begin with a 4 -week Screening/Baseline Period.  Patients 
who complete the 4 -week Screening/Baseline Period and meet all entry criteria will be randomized at Visit 2 
Allergan Confidential Protocol CGP -MD-01, Amendment 2
9(randomization visit).  The D ouble-Blind treatment period will last 12 w eeks, with a Safety Follow -up Period of
4 additional w eeks.  
There will be 8 scheduled clinic visits:  Visit 1 (Screening/Baseline), Visit 2 (R andomization), Visit 3 (Week 2), 
Visit 4 (Week 4), Visit 5 (Week 6), Visit 6 (Week 8), Visit 7 (Week 12), and Visit 8 (Safety Follow -up). For 
details, please see Table1–1, Schedule of Evaluations.
Study Population Characteristics
Number of Patients :  Approximately 810 patients will be randomized into the study
Condition/Disease :  Migraine with aura or Migraine without aura
Key Inclusion Criteria :  
Male or female patients age 18 to 75 years, inclusive, at Visit 1.
At least a 1 -year history of migraine with or without aura consistent with a diagnosis according to 
the International Classification of Headache Disorders, 3rdedition, beta version ( ICHD-3beta, 
2013; Section 12.1.1)
Age of the patient at the time of migraine onset < 50 years
History of 4 to 14 migraine/probable migraine headache days per month (see Section 6.1.1for 
definition) in the 3months prior to Visit 1in the investigator’s judgment
4 to 14 migraine/probable migraine headache days in the 28-day baseline period per electronic 
diary (eDiary)
Key Exclusion Criteria :
Has a history of migraine accompanied by diplopia or decreased level of consciousness , orretinal 
migraine as defined by ICHD -3 betaversion, 2013
Has a current diagnosis of chronic migraine, new persistent daily headache,  trigeminal autonomic 
cephalgia (eg, cluster headache), or painful cranial neuropath yas defined by ICHD -3 betaversion, 
2013
 
 
 
Usage of opioids or barbiturates >2days/month , triptans or ergots ≥10 days/month, or simple 
analgesics (eg, aspirin, non-steroidal anti -inflammatory drug s, acetaminophen) ≥15 days/month in 
the 3 months prior to Visit 1 per investigator’s judgment, or during the baseline period
(barbiturates are excluded during the baseline period and for the duration of the study [see 
Section12.2Examples of Prohibited Medications] )
Patients with clinically significant hematologic, endocrine, cardiovascular, pulmonary, hepatic, 
gastrointestinal, or neurologic disease.
Response Measures
Efficacy: Frequency of migraine or probable migraine headache days, headache days, and acute medication use
days

Allergan Confidential Protocol CGP -MD-01, Amendment 2
10 
 
 
General Statistical Methods and Types of Analyses:   All safety analyses will be performed using th e safety 
population, consisting of all patients who received at least one dose of the study treatment.  For safety analyses, 
the patients will be analyzed according to the actual treatment received at the first study treatment visit(rather 
than as randomi zed).  All efficacy analyses will be performed using the modified intent -to-treat (ITT) 
population, consisting of all randomized patients who received at least 1 dose of study treatment, had an 
evaluable baseline period of diary data, and had at least 1 evaluable post -baseline 4 -week (Weeks 1 -4, 5-8, and 
9-12) of diary data.   For efficacy analyses, the patients will be analyzed according to randomization assignment, 
regardless of actual treatment received.
The primary efficacy endpoint is the change from baseline in meanmonthly MPM headache days across the 12
-
week treatment period .  Comparisons between each dose group and placebo will be done by a mixed-effects 
model for repeated measures (MMRM) of the change from baseline .  The statistical mod el will include 
treatment group, visit and treatment group by visit interaction as categorical fixed effects.  It w ill also include 
the baseline score and baseline
-by-visit interaction as covariates.  Pairwise contrasts in the MMRM model will 
be used to ma ke the pairwise comparisons of dose to placebo.  
A sensitivity analysis will be performed on the 
primary endpoint to assess the robustness of the MMRM analysis to possible violation of the missing -at-random 
(MAR) assumption.  Th esensitivity analysis will be done using a pattern -mixture model (PMM) , under which 
data could be missing -not-at-random (MNAR), with repeated analyses combined via the multiple imputation 
(MI) procedure. An additional sensitivity, MIin conjunction w ith robust regression, will be performed in case 
of non-normality for the primary efficacy endpoint.     
Secondary efficacy endpoint s include:(1) Change from baseline in meanmonthly headache days across the 12-
week treatment period ; (2) Proportion of patients with at least a 50% reduction in meanmonthly MPM days 
across the 12-week treatment period ; (3) Change from baseline in meanmonthly acute medication use days 
across the 12-week treatment period . 
Summary tables for each treatment and for each measurement time will include the number of patients and 
descriptive statistics (mean, standard deviation, median, minimum and maximum) and/or response frequencies.
For continuous variables, pairwise comparisons will be analyzed using MM RM.  For variables where data is 
binary, comparisons between treatment groups will be done by pairwise contrasts using logistic regressions for 
variables with only one postbaseline assessment or using generalized linear mixed model for variables with 
multiple postbaseline assessments .
The overall type I error rate for multiple comparisons across a
ctive treatment doses and the primary and 
secondary efficacy parameters w ill be controlled at the 0.05 level using a graphical approach by Bretz et al
(2011). The weighting strategy of the multiple comparisons is designed to allocate initial alpha equally to the 
QD and BID dose regimen s. Within each dosing regimen, individual AGN-241689doses will be tested in a
hierarchical order from high to low  dose, i.e. for primary efficacy endpoint, low dose can be tested only if high 
dose comparison shows statistical significan ce. In addition, for a given dose comparison versus placebo , the 
strategy has the primary endpoint as gatekeeper to the secondary endpoints so that secondary endpoints can be 
tested only if primary hypothesis of the corresponding dose comparison reaches statistical significan ce. 
Weighted Bonferroni testswill be used for testing the hypotheses .A complete decision-flow graph and details 
of the graphical multiple comparison procedure will be presented in the statistical analysis plan of this study.
Sample Size Calculation :  
The assumptions and corresponding pow er assessments for the primary efficacy endpoint are shown in the table 
below. The treatment difference assumption is b ased on results from other episo dic migraine prevention studies:
the placebo -adjusted reduction in monthly migraine days ranged from 1.1 to 2 days (topiramate [Silberstein et
al, 2004and Brandes et al, 2004 ], telcagepant [Ho et al, 2014 ], and CGRP monoclonal antibodies Ph2 studies 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
11[Dodick et al, 2014; Dodick et al, 2014; Bigal et al, 2015; Sun et al, 2016 ], and their Ph3 studies results reported 
from American Headache Society & American Academy of Neuroscience 2017 ). Common standard deviation is 
estimated based on blinded interim data assessments of this study. Pow er is calculated via 10,000 simulations 
based on multiplicity adjustment .
60mg BID 
(n=90)30mg BID 
(n=90)60mg QD 
(n=180)30mg QD 
(n=180)10mg QD 
(n=90)
Assumed Treatment
differencevs. placebo
(placebo n = 180 )-1.6 -1.5 -1.5 -1.4 -1.2
Effect size
(Common SD = 3.0)0.53 0.5 0.5 0.47 0.4
Power 97.0% 91.4% 99.3% 98.1% 80.3%
QD = once daily; BID = twice daily; SD = standard deviation.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
12

Allergan Confidential Protocol CGP -MD-01, Amendment 2
13

Allergan Confidential Protocol CGP -MD-01, Amendment 2
14

Allergan Confidential Protocol CGP -MD-01, Amendment 2
15

Allergan Confidential Protocol CGP -MD-01, Amendment 2
161. Background and Clinical Rationale 
1.1Background
Migraine affects 18% of women and 6% of men in the United States with peak prevalence 
occurring between the ages of 25 -55 years.Approximately  one-third ofthesemigraineurs 
have 3or more migraine headaches per month, and over half report severe impairment or the 
need for bed rest ( Liptonet al, 2005, Lipton et al, 2007 ). In the US alone, work loss due to 
migraine is estimated to cost ~ $13 billion annually( Hu et al, 1999). Prevalence is similar in 
Europe, with migraine headache affecting on average 17.6% of women and 8% of men 
(Stovner, 2010).It is curre ntly ranked by the World Health Organization (WHO) as 19th 
among causes of disability (Katsarava et al, 2012).
Migraine is ty pically characterized by  attacks of throbbing, unilateral headache of moderate 
or severe pain int ensity, associated with nausea, vomiting, and/or sensitivity to light 
(photophobia) and sound (phonophobia).  In about 25% of individuals, the migraine 
headache is preceded b y focal neurological d ysfunction (aura). I
mproving diagnosis and 
optimizing treatments for migraine have been recognized as critically  important to 
overcoming current barriers to reduc e the global burden of migraine.
Because there are no biological markers for migraine, diagnosis is based on clinical history , 
exam, and the exclusi on of other headache disorders. Physicians appl y clinical criteria to 
guide diagnoses and subsequent treatment. Episodic migraine (EM) is a syndrome diagnosis 
applied to patients with migraine (with or without aura)who have 1- 14 headache day s per 
month. Chronic migraine (CM) is a specific ICHD-3 beta version diagnosis applied to a 
subset of patients with ≥15 headache day s per month (Katsarava et al ,2011; Olesen et al, 
2006; ICHD-3 betaversion, 2013).This study  will evaluate the efficacy, safety and 
tolerability  of AGN-241689 in patients with episodic migraine.
1.2Overview of AGN-241689
AGN-241689is a potent, selective oral calcitonin gene-relatedpeptide (CGRP)receptor 
antagonist being developed for migraine prevention. CGRP is aneuropeptide implicated in
thepathophysiology ofmigraine. CGRPlevelsinthecranialvenous outflow (i.e, external 
jugular vein) areincreased during a migraine attack and exogenous lyadministered CGRP
hasbeenshown to triggermigraine-likeheadache in migraineurs. The majority(80to 90%)
oftrigeminal Aδfibersthatinnervate theduracontainCGRP, suggesting that thesefibers
may beinvolvedinsterileneurogenic inflammation andmigraine pain transmission.
Furthermore, the CGRP receptoris present on humanmeningeal andcerebralbloodvessels.  
Theseobservations suggestthatactivation of the trigeminovascular s ystem, with release of 
Allergan Confidential Protocol CGP -MD-01, Amendment 2
17CGRP, mayplay a key roleinmigraine pathogenesis andthatinhibition ofCGRPmay yield
anoveltherapeutic approach totreating migraine.
Theability ofCGRPinhibition toinducepainreliefinthe acute treatment of migraine
wasinitially observed with anintravenous (IV) formulation ofolcegepant (Olesen et al,
2004),andreplicated by Merck & Co.,Incwithanoralformulation ofMK-0974
(telcagepant ), ahighlyselective CGRPreceptorantagonist (CGRPRA).  In phase 3
studies,telcagepant wassuperiorto placebointhe primary  endpoints of 2-hourpain
freedom, 2-hour pain relief, andthe absence of associated sy mptoms(photophobia,
phonophobia ,andnausea),aswellasthekeysecondaryendpointof 24-hour sustained pain
freedom(Connor, 2009).However, serum alanine aminotransferase (AL T) increases were 
observed with telcagepant
.  For this reason, the development of these oral CGRP  antagonists 
was stopped.
Recently, several phase 2 trials have been published thatfurther establish proof -of-concept of 
CGRP as a therapeutic target in the prevention ofepisodic and chronic migraine 
(DodickDW, Goadsby  PJ, Silberstein SD, et al ,2014; Bigal et al ,2015; Dodick DW, 
Goadsby PJ, Spierings EL ,et al, 2014).  Specifically , TEV-48125, LY-2951742 ,and ALD-
403 are injectable monoclonal antibodies shown to be efficacious in the prevention of 
migraine that act by  targeting CGRP  and blocking the CGRP  pathway thought to be involved 
in migraine pathophy siology. AGN-241689was chemically  designed to minimize the 
potential for reactive metabolites, thereb y reducing the risk of liver toxicity  that has been 
observed with telcagepant, and MK-3027.  An extensive Phase 1 program, including a 28 -
day multiple dose study  ofdoses up to 170 mg QD, has been c onducted to assess hepatic 
effects of AGN-241689. To date, no safety  signal in hepatic lab parameters has been 
observed in either preclinical or clinical studies conducted with AGN-241689.
The purpose of this stud y is to prospectively assess the safet y, tolerability and efficacy of 10-, 
30-and 60-mg once daily (QD)and 30-and 60-mg twice dail y (BID) doses of AGN-241689
compared with placebo in the prevention of episodic migraine, in a randomized, double -
blind, placebo -controlled Phase 2/3study.  This study is designed to be a pivotal trial, and 
will be used to support registration applications.
Additional information on non -clinical pharmacology , toxicology , and pharmacokinetic 
properties of AGN-241689 can be found in the Investigator ’s Brochure.  
Allergan Confidential Protocol CGP -MD-01, Amendment 2
181.3Rationale For Doses and Dose Regimens Selected 
The ability  of a CGRP  antagonist to block capsaicin induced increases in dermal blood flow 
has been used as a pharmacod ynamic assay  to determine doses which inhibit peripheral 
CGRP function and estimate potential ly effective clinical doses in migraine (Hewitt et al ,
2011; Li et al, 2014) . Based on this model, doses of AGN-241689 of 10 mg QD, 30 mg QD , 
and 60 mg QD are potentially  effective doses for migraine prevention.  I n addition, the PK 
characteristics of AGN-241689 suggest the possibility  that a BID dosing regimen may  
provide better 24 -hour CGRP  inhibition than does a QD regimen. Based on these 
considerations, this study will investigate doses of AGN-241689 10 mg, 30 mg ,and 60mg 
QD and doses of 30 mg and 60 mg BID for 12 weeks.  
Prior testing in the P hase 1 program suggests that the range of doses tested will be well-
tolerated and safe in humans.  Dail y dosing of170 mg per day  was studied in healthy  
subjects for 28 day s; this waswell-tolerated with an unremarkable AE profile and no 
significant elevations of ALT or aspartate aminotransferase (AST) were observed.  R esults 
from the 28 -day multiple dose study  and other Phase 1 studies support the safet y and 
tolerability  of the dose range tested in this protocol. 
2. Study Objectives and Clinical Hypotheses
2.1Study Objectives
To evaluate the safet y and tolerability  of the following doses and dose regimens o f 
AGN-241689 (10- mg QD, 30-mg QD, 30 -mg BID, 60-mg QD, and 60 -mg BID)for the 
prevention of episodic migraine. 
To characterize the dose/response relationship across the following doses and dose regimens 
(10 mg QD, 30 mg QD, 30 mg BID, 60 mg QD, and 60 mg BID) for the prevention of 
episodic migraine.
To prospectivel y test for supe riority of the following doses and dose regimens of 
AGN-241689 (10- mg QD, 30- mg QD, 30 -mg BID, 60- mg QD, and 60 -mg BID) versus 
placebo for the prevention of episodic migraine in thispivotal trial
2.2Clinical Hypotheses
In individuals with episodic migraine, at least one active treatment arm, 60 mg QD or 60 mg 
BIDis superior to placebo as measured by  the change from baseline in mean monthlyMPM 
days across the 12- week treatment period .
Allergan Confidential Protocol CGP -MD-01, Amendment 2
19AGN-241689has an acceptable safet y profile and is well tolerated in patie nts with episodic 
migraine.
3. Study Design
3.1Structure
This isa multi-center, randomized, double -blind, placebo -controlled, parallel group study  
conducted at approximately  75 sites in the United States.   Approximately  810 patients will 
be randomized to one of six treatment arms (placebo, 10 -mg QD, 30-mg QD, 30-mg twice 
daily, 60-mg QD, and 60 -mg twice dail y) in a 2:1:2: 1:2:1 ratio as follows ::
oPlacebo (n =180)
oAGN-241689 10- mg QD (n=90)
oAGN-241689 30- mg QD (n=180)
oAGN-241689 30- mgBID (n=90)
oAGN-241689 60- mg QD (n=180)
oAGN-241689 60- mg BID  (n=90)
More patients will be allocated to the 30-mg QD and 60- mg QD arms to maximize the power 
to detect a difference from placebo in the primary endpoint.  Although fewer patients are 
allocated to the BID regimen arms and the 10 -mg QD arm, these are still adequatel y powered 
to detect a clinicall y meaningful dif ference.  
To maintain the blind, investigational product will be administered orally  twice dail y for 
12 weeks to all patients. Patients, therefore, will receive either placebo twice daily , a morning 
dose of AGN-241689with an evening dose of placebo, or AGN-241689twice daily.  
Patientparticipation will begin with a4-weekScreening/Baseline P eriod.  Patients who 
complete the 4 -week Screening/Baseline Period and meet all entry  criteria will be 
randomized to the double -blind treatment period of the study  at Visit 2 (random ization visit).  
The double -blind treatment period will last 12 weeks, with a subsequent Safety Follow-up 
Period of4 additional weeks. There will be 8 scheduled clinic visits:  Visit 1 
(Screening /Baseline), Visit 2 (Randomization), Visit 3 (Week 2), Visit 4 (Week 4), Visit 5 
(Week 6), Visit 6 (Week 8), Visit 7/ET(Week 12), and V isit 8 (Safet y Follow-up). For details, 
please see Table1–1, Schedule of Visit and Procedures.
3.2Efficacy Assessments
Efficacy assessments will be based on information recorded by  the patient.  An eDiarywill 
be used dail y at home to collect data on headache duration, headache characteristics, 
Allergan Confidential Protocol CGP -MD-01, Amendment 2
20symptoms, and acute medication use, which will be collectivel y applied to define migraine, 
probable migraine, and headache day s per the criteria listed in Sections 6.1.1.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5Data Safety Monitoring Board
An independent 
DataSafety Monitoring Board (D SMB) will be established to review 
unblinded safet y data and summary reports, identify  any safety issues and trends, and make 
recommendations to the Sponsor , including modification or early  termination of a trial, if 
emerging data show unexpected and clinically significant AEsof treatment. 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
21Details of the DSMB memberships, standard operational procedures for data 
monitoring/review , frequency  of review , and other pertinent details will be provided in a 
separate D SMBCharter.
3.6Adjudication Committee
An Adjudication Charter will be established and will describe the process for the blinded 
surveillance, monitoring, and adjudication b y the Clinical Adjudication Committee of events 
of post-treatment elevations of ALT and/or AST≥ 3x the upper limit of normal (ULN) in the 
AGN-241689program. The purpose of this committee charter will be to provide a 
standardized process for the adjudication of data associated with these events in order to 
determine whether the elevation was related to AGN-241689.
4. Study Population and Entry Criteria
4.1Number of Patients 
Approximately  810 patients will be randomized at approximately  75 sites in the US. 
4.2Inclusion Criteria
The following are requirements for entry  into the study : 
1.Written informed consent and patient privacy  information (eg ,Written 
Authorization for Use and Release of Health and Research Stud y Information) 
obtained from the patient prior to initiation of any  study-specific procedures.
2.Male or female patients age s18 to 75 y ears, inclusive, at Visit 1.
3.At least a 1 -year history  of migraine with or without aura consistent with a 
diagnosis according to the International Classification of Headache Disorders, 3rd
edition, beta version ( ICHD-3beta, 2013; Section12.1.1)
4.Age of the patient at the time of migraine onset < 50 y ears
5.History of 4 to 14 migraine/probable migraine headache day sper month (see 
Section 6.1.1for definition) on average in the 3months prior to Visit 1 in the 
Investigator ’s judgment 
6.4 to 14 migraine/probable migraine headache days in the 28-day baseline period 
per electronic diary (eDiary)
Allergan Confidential Protocol CGP -MD-01, Amendment 2
227.Completed at least 20 out of 28 day s in the eDiary  during baseline period and is 
able to read, understand, and complete the stud y questionnaires and eDiary per 
Investigator ’s judgment.
 
4.3Exclusion Criteria
The following are criteria for exclusion fr om participating in the study :
1. Difficulty distinguishing migraine headachesfrom tension -type or other 
headaches
2.Has a history  of migraine with accompanied b y diplopia or decreased level of 
consciousness orretinal migraine as defined by  ICHD-3 betaversion, 2013
3. Has a current diagnosis of chronic migraine, new persistent daily  headache, 
trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial 
neuropath yas defined b y ICHD-3 betaversion, 2013
 
 
 
 
 
8.Usage of opioids or barbiturates >
2 days/month, triptansor ergots 
≥ 10days/month, or simple analgesics (eg, aspirin, non- steroidal anti-
inflammatory drugs[NSAIDs], acetaminophen) ≥
15 days/month in the 3 months 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
23prior to V isit 1 per investigator ’s judgment, or during the baseline period
(barbiturates are excluded during the baseline period and for the duration of the 
study[seeSection12.2Examples of Prohibited Medications] )
9.Woman 
ispregnant, planning to become pregnant during the course of the study , 
or currentlylactating. Women of childbe aring potential must have a negative 
urine pregnancy  test at Visit 1and Visit 2
 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
24 
15.Any clinically  significant hematologic, endocrine, pu lmonary, hepatic, 
gastrointestinal, or neurologic disease
If there is a history  of such a disease,but the condition has been stable for 
more than 1 year prior to V isit 1, and is judged b y the investigator as not 
likely to interfere with the patient’ s participation in the study , the patient 
may be included
16.History of acute hepatitis within 6 months of Screening (V isit 1);or chronic 
hepatitis (including nonalcoholic steatohepatitis );or a positive result on anti -
hepatitis A immunoglobulin M ( IgM)antibody, hepatitis B surface antigen, or 
anti–hepatitis C antibodytesting
 
 
 
 
 
 
 
 
20.History of malignancy  in the 5 yearsprior to Visit 1,except for adequatel y treated 
basal cell or squamous cell skin cancer , or in situ cervical cancer
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
25 
 
 
 
 
 
 
 
 
 
 
 
4.4Permissible and P rohibited Medications/T reatments
4.4.1 Permissible Medications/T reatments
Medications which are not specificall y prohibited in Section 4.4.2are allowed, with the 
following clarifications and restrictions:
The following medications for the acute treatment of migraine are allowed during the stud y:
any triptan
any ergot derivative
any opioid
any other form of analgesic (including acetaminophen)
any NSAIDagent
any antiemetic agent

Allergan Confidential Protocol CGP -MD-01, Amendment 2
26Aspirin up to 325 mg/day  is allowed for cardiac prophy laxis.
Selective serotonin reuptake inhibitors (SSRI ) or serotonin norepinephrine reuptake 
inhibitors (SNRI ) will be permitted provided that treatment is stable for at least 60 day s prior 
to screening (Visit 1) and continues without change in dose throughout the study .
Therapy considered necessary  for the patient's welfare may  be given at the discretion of the 
investigator .  If the permissibility  of a specific medication/treatment is in question, please 
contact Allergan.
4.4.2 Prohibited Medications/T reatments
The following medications are prohibited 30 day s prior to Visit 1(unless otherwise indicated)
and throughout the study  period: 
Strong and moderate cytochrome P450 3A4 (CYP3A4)inhibitors, includin g but not 
limited to:  sy stemic (oral/intravenous [I V]) itraconazole, ketoconazole, fluconazole; 
erythromycin, clarithromy cin, telithrom ycin; diltiazem, verapamil; aprepitant, 
cyclosporine, nefazodone, cimetidine, quinine, and HIV protease inhibitors
Strong and moderate CYP3A4 inducers, including but not limited to:  barbiturates (eg, 
phenobarbital and primidone), s ystemic (oral/IV) glucocorticoids, nevirapine, efavirenz, 
pioglitazone, carbamazepine, phen ytoin, rifampin, rifabutin, and St. John’s wort
Strongorganic anion transporting pol ypeptide 1B1 (OATP1B1 )inhibitors (eg, 
gemfibrozil) 
Drugs with narrow therapeutic margins with theoretical potential for CYP drug 
interactions (eg,warfarin)
Medications with demonstrated efficacy  for theprevention of migraine (eg, amitriptyline, 
topiramate, propranolol ). Refer to Section 12.3.
Botulinum toxin injections ( eg, Botox®) into areas of the head, face, or neck within 6 
months prior toVisit 1 and throughout the stud y period
Acupuncture , TENS(transcutaneous electrical nerve stimulation) , cranial traction, 
nociceptive trigeminal inhibition or occipital nerve block treatments, or dental splints for 
headach
e, within 4 weeks prior to entry  into the baseline phase at week - 4 or at any  time 
during the stud y (including the week -4 to day 1 baseline phase)
Allergan Confidential Protocol CGP -MD-01, Amendment 2
27The decision to administer a prohibited medication/treatment is done with the safet y of the 
study participan t as the primary  consideration.  When possible, Allergan should be notified 
before the prohibited medication/treatment is administered.
4.4.3 Definition of Females of (Non -)Childbearing Potential and/or 
Acceptable Contraceptive Methods
For purposes of this study , females will be considered of childbearing potential unless they  
are naturall y postmenopausal (ie, no menses for 2 y ears) or permanently  sterilized (ie, 
bilateral tubal ligation, bilateral salpingectom y, bilateral oophorectom y,or hysterectom y).  
For women of childbearing potential who may  participate in the study , the following methods 
of contraception, if properly used, are generall y considered reliable: hormonal contraceptives
(ie, oral, patch, vaginal ring, injection, implant) , male condom with in travaginal spermicide, 
diaphragm or cervical cap with spermicide, intrauterine device, vasectomized partner ,or 
sexual abstinence.
For males who may participate in the study , the following methods of contraception, if 
properly used, are generally  considered reliable: post-bilateral vasectomy , barrier 
contraception or sexual abstinence. Male participants must also refrain from donating
sperm during the course of the study .
The investigator and each patient will determine the appropriate method of contracepti on for 
the patient during the participation in the study .
If a female becomes pregnant during the stud y, the investigator will notify  Allergan
immediately after the pregnancy  is confirmed and the patient will be exited from the study  
after appropriate safety  follow-up.  The investigator will (1) notify the patient’ s physician 
that the patient was being treated with an investigational drug AGN-241689and (2) follow 
the progress of the pregnancy .  The investigator must document the outcome of the 
pregnancy  and provide a copy  of the documentation to Allergan.
4.4.4 Special Diet or Activities 
Patients should refrain from consuming grapefruit or grapefruit juice from the time the 
consent form is signed until completion of the study .  Patients should alsorefrain from 
making significant changes to their diet or caf feine intake during the study .
Alcohol intake should be limited to no more than 3 drinks per day throughout the study .  A 
drink is defined as a 12 -ounce can/bottle of beer , a 4-ounce glass of wine, or 1 ounce of 
liquor.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
285. Study Treatments 
5.1Study Treatments and Formulations
Over-encapsulated tablets containing 10 -mg , 30-mg 
 and 60-mg  of AGN-241689
5.2Control Treatment(s) 
Placebo over-encapsulated tablets 
5.3Methods for Masking/Blinding
All study treatments will be provided in identical blister cards to maintain masking of the 
study.
Over-encapsulation will also be implemented to maintain study  masking, and all patients will 
be instructed to take investigational product twice daily (one capsule in the morning and one 
capsule in the evening) at approx imately the same times each day .  Patients, therefore, will 
receive either placebo twice daily , a morning dose of AGN-241689with an evening dose of 
placebo, or AGN-241689twice daily .  
5.4Treatment Allocation Ratio and Stratification 
Patients will be rando mized to the following 6 arms  in a 2:1:2:
1:2:1ratio:
Placebo (n =180)
AGN-241689 10- mg QD (n=90)
AGN-
241689 30- mg QD (n=180)
AGN-
241689 30- mg BID (n=90)
AGN-
241689 60- mg QD (n=180)
AGN-
241689 60- mg BID  (n=90)
No stratification will be performed.
5.5Method for Assignment to Treatment Gr oups/Randomization
Prior to initiation of study  treatment, each patient who provides informed consent will be 
assigned a patient 
number that will serve as the patient identification number on all study  
documents.

Allergan Confidential Protocol CGP -MD-01, Amendment 2
29Central implementation of by -site randomization will be used for this study to assign patients 
into treatment groups.   
At the time of randomization (i.e., V isit 2), eligible patients will be randomized by  blocks in 
a 2:1:2:1:2:1 ratio into the following arms: placebo, 10- mg AGN-241689QD, 30-mg AGN-
241689QD, 30-mg AGN-241689twice daily , 60 -mg AGN-241689QD, and 60- mg AGN-
241689twice daily .
An automated interactive web response sy stem  (IWRS)will be used to manage the 
randomization and treatment assignment based on a randomization scheme prepared by  
Allergan Biostatistics.
Investigational product will be labeled with medication kit numbers.  The IWRS sy stem will 
provide the site with the specific medication kit number(s) for each randomized patient at the 
time of randomization.  Sites will dispense investigational product  according to the IWRS 
instructions.  Sites will a lso log onto the I WRS at subsequent visits to obtain a kit number for 
dispensing investigational product . Sites will receive the I WRS confirmation notifications for 
each transaction.  All notifications are to be maintained with the study  source documents.
5.6Treatment Regimen and Dosing
Treatments to be used in this trial are listed in ( Table 5–1 ).  Patients who meet all of the stud y 
entry criteria at Visit 2 will be rando mized and provided with investigational product to be 
taken on an outpatient basis.  Sites will subsequently  dispense investigational product to 
patients at V isits 3, 4, 5, and 6.  Patients will take their first dose of investigational product at 
the clinic at Visit 2 (Section 8.5) and will be instructed to take their investigational product
twice dail y (approximately  12 hours interval between doses)  at approximately the same 
times each day .  Investigational product will be administered orally  for 12 weeks, and 
patients will be followed for 4 weeks following discontinuation of the investigat ional 
product.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
30Table 5–1 Study Treatments 
Drug/DoseInvestigational 
Product
FrequencyInvestigational Product
Administration (AM/PM)Route of Adm inistration
Placebo Twice Daily Placebo/
PlaceboOral (capsule)
AGN-24168910 mg 
QDTwiceDaily AGN-24168910 mg/
PlaceboOral (capsule)
AGN-24168930 mg 
QDTwiceDaily AGN-24168930 mg/
PlaceboOral (capsule)
AGN-24168930 mg 
BIDTwice Daily AGN-24168930 mg/
AGN-24168930 mgOral (capsule)
AGN-24168960 mg 
QDTwiceDaily AGN-24168960 mg/
PlaceboOral (capsule)
AGN-24168960 mg 
BIDTwice Daily AGN-24168960 mg/
AGN-24168960 mgOral (capsule)
5.7Storage of Investigational pr oducts/Treatments
The investigational product must be storedat room temperature in a securely locked cabinet. 
Further details regarding the storage of the investigational product are in the Study  Reference 
Manual.
6. Response Measures and Summary of Data Collection Methods
6.1Efficacy Measur es
Efficacy assessments will be based on information recorded by  the patient.  An eDiarywill 
be used dail y at home to collect data on headache duration, headache characteristics, 
symptoms, and acute medication use, which will be collectivel y applied to defin e migraine, 
probable migraine, and headache day s per the criteria listed in Sections 6.1.1.  The HIT -6, 
ACM-I, EQ-5D-5L, PGIC, WPAI-SHPV2.0,and Patient Satisfaction with Study  Medication
will be administered in an electronic tablet ( eTablet)at the clinic visits.
6.1.1 Efficacy Measur es
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
31 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
32 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
33 
 
 
 
 
 
  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
34 
 
 
 
 
 
 
 
 
 
 
 
6.3Future Biomedical Research
Blood samples will be collected from all patients who consent to participate in the substudy , 
for the purposes for Future Biomedical Research. The sampleswill be obtained at the 
Screening V isit. All samples will be sent to the designated central laboratory and shipped to a 
biorepository  for storage.  Please refer to the Central Laboratory Manualfor the genetic 
blood sampling procedures, shipping instructions, and contact information. Anonymized
samples may  be stored in the biorepository  database for potential analy sis under separate 
protocols for up to 15 years. Samples may be stored for a longer time if a regulatory  or 
governmental authorit
y has active questions that are being answered . Inthis special 
circumstance, samples will be stored until these questions have been adequately  addressed.
The anon ymized genetic material from the blood samples may also be used for future, 
unspecified research, not limited to the disease being studied in this particular clinical study .
All subjects enrolled in the clinical trial will be considered for enrollment in the Future 
Biomedical Research substudy ; however, participation is optional and will require a separate 
informed consent form. A patient who initially  consents can withdraw that consent at an y 
time and have his or her sample destro yedincluding an y by-products of the sample whenever 
possible.

Allergan Confidential Protocol CGP -MD-01, Amendment 2
356.4Safety Measures
6.4.1 Adverse Events
Subjective AEs will be collected from the time of consent through the last visit. For all AEs, 
the Investigator must provide an assessment of the severity, causal relationship to the 
investigational product, start and stop dat e, and seriousness of the event (eg, serious adverse 
event [SAE] ), document all actions taken with regard to the investigational product , and 
detail any other treatment measures taken for the AE. For events noted as serious adverse 
events (SAEs), the Spons or must be notified immediately  to meet their reporting obligations 
to appropriate regulatory  authorities.
6.4.2 Events of Clinical Interest
Selected non -seriousand serious events are of clinical interest and will require immediate 
reporting, recording and follow- up. The following events will be closel y monitored:
Suicidal ideations with intent, with or without a plan, (ie, Ty pe 4 or 5 on the C- SSRS)or 
any suicidal behaviors
Elevated ALT or AST lab value that is ≥ 3x the ULN
Potential Hy ’s law cases: elevated ALT or AST lab value that is ≥ 3x the ULNand an 
elevated total bilirubin lab value that is ≥ 2x the ULNand, at the same time, an alkaline 
phosphatase lab value that is <2 x the ULN.
Reporting requirements for ALT or AST elevations and potential Hy’s law cases are outlined 
in Sections 
9.5and 9.5.1.Responses to the C -SSRS that meet the above criterion will 
captured in the eT ablet and monitored by  Allergan. Events that are determined to be AEs or 
SAEs must be repor ted appropriatel y via the designated eCRF pages and forms. 
6.4.3 Clinical Laboratory Determinations
Blood and urine samples for clinical laboratory  tests will be collected at the visits outlined in 
Table1–1. Hematology , chemistry , and urinal ysis will be conducted at these visits. Serology , 
coagulation parameters ( INR),and the Urine drug screen will be conducted at Screening 
(Visit 1). The investigator will assess the clinical significance of any  values outside the 
reference ranges provided by  the central laboratory . Patients with abnormalities judged to be 
clinically significant at Screening (V isit 1) or with positive results on the urine drug screen 
will be excluded from the study . 
Allergan Confidential Protocol CGP -MD-01, Amendment 2
36Women of childbearing potential will be required to have a urine pregnancy test at all visi ts. 
A positive pregnancy  test at Visit 1 or Visit 2 will exclude the patient from participation in 
the study.  
Investigators may  also perform unscheduled clinical laboratory  determinations at any  time 
for the purpose of patient safety . 
Patients are not r equired to fast overnight before coming in for their appointments.
The clinical laboratory  parameters to be measured are shown in Table6–1.
Table6–1 Clinical Laboratory Param eters
Category Parameter
ChemistrySodium, potassium, chloride, bicarbonate, glucose, blood urea nitrogen, creatinine, 
total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine 
aminotransferase, lactate dehydrogenase, creatine kinase, total protein, albumin, 
calcium, phosphorus, uric acid, total cholesterol. The estimated glomerular 
filtration rate will be calculated by the central laboratory.
HematologyHemoglobin; hematocrit; red blood cell count; red blood cell indices (mean 
corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin 
concentra tion); white blood cell count, including differential (neutrophils, 
lymphocytes, monocytes, eosinophils, and basophils); platelet count
UrinalysisUrine dipstick for specific gravity, pH, protein, glucose, ketones, bilirubin, and 
blood; microscopic exam i ncluding red blood cells/high -power field, white blood 
cells/high -power field, and casts/low -power field.
Coagulation At Visit 1 only: international normalized ratio 
SerologyAt Visit 1 only: a nti-hepatitis A IgM antibody, hepatitis B surface antigen, anti–
hepatitis C antibody
Urine Drug ScreenScreening for drugs of abuse (eg, marijuana, cocaine, phencyclidine, 
amphetamines, benzodiazepines, barbiturates, opiates) w ill be conducted using a 
urine drug screen at Visit 1. If positive, the urine drug screen may be repeated w ith 
permission from Allergan; a negative result or an explanation of a positive result 
because of concomitant medication use (eg, opioids prescribed for migraine pain)
will be required for randomization.
A central laboratory  will be used to evaluate all urine and blood samples, which will be 
collected, processed, and stored according to the instructions provided by  the labora tory.
6.4.4 Vital Signs
Vital sign measurements, including sitting and standing blood pressure (BP), sitting and 
standing pulse rate, respiratory  rate, temperature, body  weight, and height (at Visit 1 only), 
will be performed at every  visit. Sitting and standing BP and pulse rate will be determined as 
follows: BP  and pulse measurements will be performed after the patient sits quietly  for 
5minutes, followed by  a second set of measurements taken after the patient stands for at 
least 3minutes (but no longer than 1 0 minutes).
Allergan Confidential Protocol CGP -MD-01, Amendment 2
376.4.5 Physical Examination
A complete ph ysical examination will be performed at the visits outlined in Table1–1. A 
professionall y trained physician or healthcare professional licensed to performed physical 
examinations wi ll examine the patient for an y detectable abnormalities of the following bod y 
systems:  general appearance; neck (including thyroid); head, ey es, ears, nose, and throat; 
lungs; heart/cardiovascular; abdomen; neurologic; extremities; back; musculoskeletal; 
lymphatic; skin; and other . The neurologic examination should be conducted to detect the 
presence of an y significant sensory /motorabnormalities.
6.4.6 Electrocardiograms
A 12-lead ECG will be performed at the visits outlined in Table1–1. All ECGs should be 
performed after the patient has been supine for at least 5 minutes. A copy of the ECG will be 
saved as a source document. ECGs will be transmitted electronicall y to the central ECG 
laboratory  for analysis according to the instructi ons provided by  the laboratory to be centrally  
read by a cardiologist. The overall interpretation of the clinical significance of the ECG will 
be determined b y the investigator and recorded in the patient’ s eCRF.
6.4.7 Columbia -Suicide Severity Rating Scale (C -SSRS)
The C-SSRS is a clinician -rated instrument that reports the severit y of both suicidal ideation 
and behavior . Suicidal ideation is classified on a 5 -item scale: 1 (wish to be dead), 
2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods [not 
plan] without intent to act), 4 (active suicidal ideation with some intent to act, without 
specific plan), and 5 (active suicidal ideation with specific plan and intent). The C -SSRS also 
captures information about the intensity  of ideation, specifically the frequency , duration, 
controllability , deterrents, and reasons for the most severe t ypes of ideation. Suicidal 
behavior is classified on a 5 -item scale: 0 (no suicidal behavior), 1 (preparatory  acts or 
behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 
1classification can be selected provided they  represent separate episodes. For actual attempts 
only, the actual or potential lethality  is classified for the initial, most lethal, and most recent 
attempts. The C-SSRS will be completed at all study  visits. At Visit 1(Screening) the 
C-SSRS will be completed for the patient’ s lifetime history  of suicidal ideation and behavior . 
At all other visits the C -SSRS will be completed for ideation and behavior since the previous 
visit. The C-SSRS will be completed on the eTabletby the investigator or designee with 
current and valid training in administering the assessment. A patient should not be released 
from the study  center until the results of C -SSRS are r eviewed and it is confirmed that the 
patient is not considered to be at risk.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
386.5Other Study Supplies
The following will be provided by  Allergan or a delegate of Allergan’ s:
All supplies needed for blood and urine sampling (central laboratory anal ysis, urine 
culture/sensitivity ), and urine dipstick reagent strips
All supplies needed for PK sample collections 
Shipping materials for shipment of laboratory  samples to central laboratory
All supplies needed for ECG assessment including ECG machine 
Electronic diar ies
Electronic tablets
6.6Summary of Methods of Data Collection
An IWRS will be used to randomize patients and manage investigational product inventory . 
All office visit data (ie, non- diary data) for this study  will be collected by  either the eT ablet 
(eg, questionnaires for patient reported outcomes) or eCRFs via an electronic data capture 
system. Source documents will be used at the sites and may  include a patient’ s medical 
record, hospital charts, clinic charts, the investigator ’s patient study  files, as wel l as the 
results of diagnostic tests such as laboratory  tests, ECGs, etc. A centralized clinical 
laboratory  will be used for the anal ysis of all blood and urine samples , and for ECG 
assessments . Additional information on the collection and handling of samples is detailed in 
the Lab Procedure Manual.
Patients will use an eDiary dail y to record the daily total duration of headache, headache 
characteristics, associated sy mptoms, the worst pain severity , and acute medication use both 
in the Screening/Baseline P eriod and double -blind treatment period until Visit 8.  Training for 
the eDiary  will be provided for qualified patients during the Screening/Baseline visit 
(Visit1).
7. Statistical Pr ocedures
7.1Analysis Populations
All safety analyses will be performed using t he safety population, consisting of all patients 
who received at least one dose of the study  treatment.  For safet y data analyses, the patients 
will be anal yzed according to actual treatment received (rather than as randomized).  The 
Intent-to-Treat (ITT) Population will consist of all randomized patients. All efficacy analyses 
will be performed using the modified intent-to-treat (ITT) population, consisting of all 
Allergan Confidential Protocol CGP -MD-01, Amendment 2
39randomized patients who received at least 1 dose of study  treatment, had an evaluable 
baseline period of diary  data, and had at least 1 evaluable post- baseline 4- week (Weeks 1-4, 
5-8, and 9-12) of diary  data.  For efficacy  data analy ses, the patients will be anal yzed 
according to randomization assignment, regardless of actual treatment received.
7.2Collection and Derivation of Primary and Secondary Efficacy 
Assessments
For analy sis purposes, four weeks (28 day s) will be considered as one month. On a daily 
basis during the 28-day  baseline period and throughout the double -blind treatment period, 
patients are to record into an eDiaryinformation on the daily total duration of headache, 
headache specific characteristics and s ymptoms,the worst pain severity ,and use of an y acute 
headache pain medication.  Patients will be able to report headache data, including absence 
of headache, for the day  of the diary  report and for the day  immediatel y prior to the day  of 
the diary report, as long as information reported is for a time subsequent to the patient’ s most 
recent report.  This is defined as a one -day “missing -recall” window .  
Following randomization on Day  1, there are 4 visits at 2 -week intervals, followed by  2 visits 
at 4-week intervals; altogether encompass ing a 12-week double -blind treatment phase of the 
study and a 4-week safety  follow-up phase. In practice, there may  or may not be exact 2 -
week or 4 -week durations between two consecutive visits and the visits might not align with 
each 28-day period recorde d in the eDiary  (ie, weeks 1 -4, 5-8 and 9-12, corresponding to 
days 1-28, 29-56 and 57- 84).  Therefore, for data anal ysis purposes, the number of 
migraine/probable migraine headache day sduring the first 28 day s of the baseline phase, 
starting with the day of the screening visit, will serve as the “baseline”, and change from 
baseline will be calculated for consecutive 28 -day periods beginning with Day  1.
In order to be randomized, a patient should be in the baseline phase for at least 28 day s and 
must repor t diary data for at least 20 day s (including missing recall) during the 28- day 
baseline period.  If less than 28 day s of baseline data are reported, the number of headache 
days and other such counting variables for “baseline” will be prorated to standardiz e the 
count to a 28 -day equivalent.  Subsequent to treatment start, the number of headache day s 
will be counted in successive and non -overlapping 4 -week (ie, 28 -day) windows.  Headaches 
that continue into a subsequent 4 -week period will be counted (with re corded severit y and 
duration) as occurring in each period.  
If any diary window for a patient has at least 12 but less than 28 day s of reported data, the 
prorated approach will be used.  If a patient reports less than 12days of headache data, the 
patient’s observed countsin that particular 28 -day dairy window will be set to missing for 
Allergan Confidential Protocol CGP -MD-01, Amendment 2
40that window .  Theseprorating rule swill be applied to all ef ficacy analyses of diary  data 
unless otherwise stated.  
7.2.1 Primary Efficacy Variable
The primary  efficacy variable is the change from baseline in mean monthly  MPM headache 
days across the 12- week treatment period. Baseline is defined as the number of MPMdays 
during the first 28 day s of the screening/baseline period, starting with the day  of the 
screening visit.   
7.2.2 Secondary Efficacy Variables
The 3secondary  efficacy variables include:
Change from baseline in mean monthly  headache day s across the 
12-week treatment 
period
.
Proportion of patients with at least a 50% reduction in mean monthly  MPMheadache 
days across the 12-week treatment period .
Change from baseline in mean monthly  acute medication use day sacross the 
12-week 
treatment period
 
 
 
  
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
41 
 
 
 
 
 
7.3Hypothesis and Methods of Analysis
7.3.1 Primary Efficacy Analyses
The primary  efficacy analysis is on the change from baseline in the mean monthly  MPM 
headache day s acrossthe12-week treatment period . The primary null h ypothesis is that 
AGN-241689treatment doses 10 mg QD, 30 mg QD, 60 mg QD, 30 mg BID and 60 mg BID 
are each equall
y effective to placebo in decreasing from baseline the number of headache 
days per 4 weeks.  The alternative hy pothesis is that at least one of those fivedoses of AGN-
241689has a different effect than placebo.  
The primary  comparison between treatment groups will be done by  a mixed-effects model for 
repeatedmeasures (MMRM) of the change from baseline.  The statistical model will include 
treatment group, visit and treatment group b y visit interaction as categorical fixed ef fects.  It 
will also include the baseline score and baseline -by-visit interaction as covariates.  Pairwise 
contrasts in the MMRMmodelwill be used to make the pairwise comparisons of each dose 
to placebo . 
  

Allergan Confidential Protocol CGP -MD-01, Amendment 2
42Asensitivity  analysis will be performed on the primary  endpoint to assess the robustness of 
the MMRM analy sis to possible violation of the missing -at-random (MAR) assumption.  The
sensitivity  analysis will be done using a pattern- mixture model (PMM), under which data 
could be missing -not-at-random (MNAR), with repeated anal yses combined via the 
reference-based multiple imputation (MI) procedure. An additional sensitivity , MIin 
conjunction with robust regression, will be performed in case of non -normality  for the 
primary efficacy endpoint.      
7.3.2 Secondary Efficacy Analyses 
The secondary  efficacy variables are identified in rank order in Section 7.2.2.  The overall
type I error rate for multiple comparisons across active treatment doses and the primary  and 
secondary  efficacy parameters will be controlled at the 0.05 level using a graphical app roach 
by Bretz et al (2011).  The weighting strategy of the multiple comparisons is designed to 
allocate initial alpha equally  to the QD and BID dose regimens . Within each dosingregimen, 
individual AGN-241689doses will be tested in a hierarchical order from high to low dose, 
i.e. for primary  efficacy endpoint, low dose can be tested only
 if high dose comparison shows 
statistical significance. In addition, for a given dose comparison versus placebo, the strate gy 
has the primary  endpoint as gatekeeper to the secondary  endpoints so that secondary  
endpoints can be tested only  if primary  hypothesis of the corresponding dose comparison 
reaches statistical significance. Weighted Bonferroni tests will be used for test ing the 
hypotheses.A complete decision- flow graph and details of the graphical multiple comparison 
procedure will be presented in the statistical anal ysis plan of this study .
For continuous variables, pairwise comparisons will be anal yzed using MMRM , with
baseline covariate .  For variables where data is binary , comparisons between treatment 
groups will be done b y pairwise contrasts usinglogistic regressions for variables with only  
one postbaseline assessment or using generalized linear mixed model for var iables with 
multiple postbaseline assessments.
 
  
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
43 
    
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
447.6Subgroup Analyses
There are no planned subgroup anal yses.
7.7Sample Size Calculation
The assumptions and corresponding power assessments for the primary  efficacy endpoint are 
shown in the table below. The treatment difference assumption is based on results from other 
episodic migraine prevention studies: the placebo- adjusted reduction in monthly  migraine 
days ranged from 1.1 to 2 day s (topiramate [Silberstein et al , 2004and Brandes et al , 2004], 
telcagepant [Ho et al, 2014] , and CGRP monoclonal antibodie s Ph2 studies [ Dodick et al , 
2014; Dodick et al, 2014; Bigal et al, 2015; Sun et al, 2016], and their Ph3 studies results 
reported from American Headache Societ y & American Academy  of Neuroscience 2017 ). 
Common standard deviation is estimated based on blinded interim data assessments of this 
study. Power is calculated via 10,000 simulations based on multiplicity  adjustment.
60mg BID 
(n=90)30mg BID 
(n=90)60mg QD 
(n=180)30mg QD 
(n=180)10mg QD 
(n=90)
Assumed Treatment
differencevs. placebo
(placebo n = 180 )-1.6 -1.5 -1.5 -1.4 -1.2
Effect size
(Common SD = 3.0)0.53 0.5 0.5 0.47 0.4
Power 97.0% 91.4% 99.3% 98.1% 80.3%
QD = once daily; BID = twice daily; SD = standard deviation.
7.8Interim Analyses
There is no interim analysis planned.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
458. Study Visit Schedule and Procedur es
Please see Table1–1for a schedule of visits and procedures and Figure 1for a study  visit 
flowchart.
8.1 Patient Entry Procedures
8.1.1 Overview of Entry Procedures
Prospective patient s as define d by the criteria in Section s4.3and4.4(inclusion/exclusion 
criteria) will be considered for entry  into this study .
8.1.2 Informed Consent and PatientPrivacy
The study  will be discussed with the patient and a patientwishing to partici pate must give 
informed consent prior to any  study-related procedures or change in treatment.  The patient
must also g ive authorization and other written documentation in accordance with local 
privacy requirements (where applicable) prior to any  study-related procedures or change in 
treatment.
Each patientwho provides informed consent and/or assent will be assigned a patient number 
that will be used on patientdocumentation throughout the study .
The investigator or qualified designee will explain the PK a nd future biomedical research 
consents to the patient and answer all of his/her questions. Patients will sign separate consent 
forms to participate in the PK substudy  and future biomedical research before performing 
any procedure related to the substudies, respectively .
8.2Washout Intervals
This study  will not include a washout period .  
8.3Procedures for Final Study Entry 
At the Screening and Randomization visits (V isits 1 and 2), patients must meet all of the 
inclusion criteria and must not meet any  of the exc lusion criteria. Rescreening of patients 
may be considered with permission from Allergan. Also, all females of childbearing potential 
must have negative results on the urine pregnancy  test at the Screening and Randomization 
visits (Visits 1 and 2, prior to the first administration of investigational product).
Allergan Confidential Protocol CGP -MD-01, Amendment 2
46Priorto randomization, confirm that the patient had 4 to 14 migraine/probable migraine 
headache day s  and < 15 headache day s duringthe 28-day baseline period (see Section 6.1.1
for definition) and c ompleted the eDiary  
for at least 20 of the 28 day s.
See Section 5.5for the method for assignment to treatment groups/ randomization.
 
 
 
 
 
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
47 
 
 
 
 
 
 
 
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
48 
 
 
 
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
49 
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
50 
 
8.5Instructions for the Patients
Section 4.4.4 provides diet and activity  instructions for patients enrolled in the study .
Patients will be provided with instructions on daily completion of the eDiary . A practice 
session with a hy pothetical scenario should be administered to ensure the patients’  
comprehension of the questions and the information to be entered . In addition, prohibited 
medications should be reviewed with the patients. Patients will be instructed to bring their 
eDiary to each clinic visit and return their investigational product
(used and unused).
Patients should be instructed to take investigational product twice daily  at approximately  the 
same times each day (approximately  12 hours between doses) .For dosing on Day  1 (Visit 2), 
the first dose is to be taken at the study  site, and patients should be advised to take the second 
dose depending on the time of the site visit and the patient’ s usual routine. 
Patientsshould use appropriate contraceptive measures for the durationof their participation 
in the study . (See Section4.4.3)

Allergan Confidential Protocol CGP -MD-01, Amendment 2
518.6Unscheduled Visits
Additional examinations and laboratory  assessments may  be performed as necessary  to 
ensure the safet y and well -being of the patients during the stud y period. Unscheduled visit 
eCRFs should be completed for each unscheduled visit .
8.7Compliance with Pr otocol
All assessments will be conducted at the appropriate visits as outlined in Table1–1,and the 
timing of the visits should occur as close as possible to the day  specified. At each visit, the 
patient will be asked if the patient changed the dose/regimen of any  existing concomitant 
medications orinitiated the use of an y new concomitant medications since the last visit to 
ensure compliance with the protocol. 
Investigational product compliance during an y period will be closely monit ored by counting 
the number of tablets dispensed and returned. E very effort will be made to collect all unused 
investigational product.
8.8Early Discontinuation of Patients
A premature discontinuation will occur when a patient who signed the informed consent form 
(ICF) and has been randomized ceases participation in the study , regardless of circumstances, 
before completion of the study . Patients can be prematurely  discontinued from the study  for 
one of the following reasons:
Adverse event (AE)
Lack of ef ficacy
Withdrawal of consent (a clear reason must be documented)
Lost tofollow-up(Every effort must be made to contact the patient; a 
certified/traceable letter must be sent.)
Pregnancy
Protocol violation
Non-compliance with study drug
Study terminated by  Sponsor
Site terminated by  Sponsor
Other 
Allergan Confidential Protocol CGP -MD-01, Amendment 2
52Patients may  voluntaril y withdraw from the stud y at any time. Notification of earl y patient 
discontinuation from the study  and the reason for discontinuation will be clearl y documented 
on the appropriate case report form. All randomized patients who prematurely  discontinue 
from the study , regardless of cause, should be seen for final study assessment s. The final 
assessment s will be defined as completion of the evaluations scheduled for V isit 7/Early 
Termination and Visit 8 Safety Follow-up,4 weeks post the last dose of I P.
8.9Withdrawal Criteria
Women who become pregnant (Section 9.4) and patients who meet investigational product 
discontinuation criteria related to abnormal liver function tests (Section9.5) and advised not 
to be re-challenged will be withdrawn from the study and should refrain from taking 
investigational product. The patient should return to the clinic for earl y termination
procedures (V isit 7)and the Safet y Follow-up Visit 8. Patients who reply  with “yes” to 
questions 4 or 5 in the suicidal ideation section or “y es” to any  question in the suicidal 
behavior section of the C- SSRS at Visits 3 through 6 must be withdrawn from the study and 
should receive appropriate follow -up as in routine clinical practice , including the Early 
Termination Visit 7and the Safet y Follow-Up Visit 8.
A patient with a condition and/or a situation that, in the investigator's opinion, may  put the 
patientat significant risk, may  confound the study  results, or may  interfere significantl y with 
the patient's participation in the study  may be withdrawn from treatment.
8.10Withdrawal from Future Biomedical Research
A patient who initially  consents can withdraw th at consent at an y time and have his or her 
sample destro yed, including an y by-products of the sample whenever possible. If a patient 
withdraws consent, their phy sical sample will be destroy ed and no new health information 
identifying the patient will be ga thered after that date. However , once the genetic data is 
anonymized and placed into the biorepository  database after stud y database lock, the 
information cannot be withdrawn .
8.11Study Termination
The study  may be stopped at his/her study  site at any  time by the site investigator .  Allergan 
may stop the study  (and/or the study site) for any reason, with appropriate notification.
9. Adverse Events
AEs occurring during the studywill be recorded on a n AEcase report form .  If AEs occur, 
the first concern will be the safety of the study participants.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
539.1Definitions
9.1.1 Adverse Event
An AEis any untoward medical occurrence in a patient or clinical investigation patient
administered a pharmaceutical product and that does not necessarily  have a causal 
relationship with this treatment. An AEcan therefore be an y unfavorable and unintended 
sign (including an abnormal laboratory  finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.  In addition, duringthe screening period, AEswill be assessed 
regardless of the administration of a pharmaceutical product .
Note:  AEsmust be collected once informed consent has been obtained, regardless of 
whether or not the patienthas been administered study  drug.
Progression of treatment indication including new or worsening of anticipated clinical signs 
or symptoms, which are collected as clinical efficacy  variables and assessed as unequivocall y 
associated with the disease p rogression and /or lack of efficacy , should NOT  be reported as 
AEsunless the disease progression is greater than anticipated in the natural course of the 
disease.
AEs will be assessed,documented , and recorded in the e CRFthroughout the study (ie, after 
informed consent has been obtained ).  At each visit, the investigator will begin by  querying 
for AEs by asking each patienta general, non-directed question such as “ How have you been 
feeling since the la st visit?”  Directed questioning and examination wil l then be done as 
appropriate.  All reported AEs will be documented on the appropriate case report form.
9.1.2 Serious Adverse Event
An SAE is a ny AEoccurring at any  dose that results in any  of the following outcomes: 
death, a life -threatening AE, inpatient ho spitalization or prolongation of existing 
hospitalization, a persistent or significant disability/incapacity , or a congenital anomaly /birth 
defect.Important medical events that may  not result in death, be life -threatening, or require 
hospitalization may  be considered a SAEwhen, based upon appropriate medical judgment, 
they may jeopardize the patient and may  require medical or surgical intervention to prevent 
one of the outcomes listed in this definition.  (See Section 9.3for procedures for reporting a n
SAE.)
Allergan considers all cancer adverse events as SAEs. In addition, Allergan considers an y 
abortion (spo ntaneous or nonspontaneous) as an SAE.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
54Pre-planned surgeries or procedures for pre -existing, known medical conditions for which a 
patientrequires hospitalization is not reportable as a n SAE.
Any pre-planned surgery or procedure should be clearl y documented in the site source 
documents by  the medically  qualified investigator at the time of the patient’s entry into the 
study.  If it has not been documented at the time of the patient ’s entry into the study , then it 
should be documented as a SAEand reported to Allergan.
9.1.3 Severity
A clinical determination will bemade of the intensity  of an AE.  The severity assessment for 
a clinical AEmust be completed using the following definitions as guidelines:
Mild Awareness of sign or s ymptom, but easily  tolerated.
Moderate Discomfort enough to cause interference with usual activity .
Severe Incapacitating with inability  to work or do usual activity .
9.1.4 Relationship to Study Drug or Study Procedure
A determination will be made of the relationship (if an y) between an AEand the study  drug
or study procedure , as applicable .  A causal relationship is present if a determination is made 
that there is a reasonable possibility  that the AEmay have been caused by  the drug or study 
procedure .
9.2Procedures for Reporting Adverse Events
Any adverse event must be recorded on the appropr iate case report form.
All SAEs that are drug -related and unexpected (not listed as treatment -related in the current 
Investigator's Brochure) mustbe reported to the governing Institutional Review 
Board/Independent Ethics Committee ( IRB/IEC)as required b ythe IRB/IEC, local 
regulations, and the governing health authorities.   Any adverse event that is marked ‘ongoing’  
at the exit visit must be followed- up as appropriate.
9.3Procedures for Reporting a Serious Adverse Event
Any SAEoccurring during the stud y period (beginning with informed consent) and for at 
least 30 day s after the last dose of study  drug must be immediately  reported but no later than 
24 hours after learning of a nSAE.  SAEsmust be reported to Allergan (or Agent of Allergan) 
Allergan Confidential Protocol CGP -MD-01, Amendment 2
55as listed on the Allergan Study Contacts Page and recorded on the SAEform.  All patients 
with anSAEmust be followed up and the outcomes reported.  The investigator must supply 
the sponsor and the IRB/IEC with an y additional requested information (eg, autopsy  reports 
and discharge summaries ).
In the event of a nSAE, the investigator must:
1.Notify Allergan immediately  by faxor email using the SAEform(contact details can 
be found on page 1 of the SAEform); phone numbers and relevant Allergan 
personnel contacts are also o n the front page of protocol and Study  Contacts Page.
2. Obtain and maintain in his/her files all pertinent medical records, information, and 
medical judgments from colleagues who assisted in the treatment and follow -up of 
the patient .
3.Provide Allergan with a complete, written description of the adverse event(s) on the 
SAEform describing the event chronologically , including an y treatment given (eg, 
medications administered, procedures performed) for the adverse event(s).  
Summarize rele vant clinical information about the event:  signs, s ymptoms, 
diagnosis, clinical course and relevant clinical laboratory  tests, etc.  Include any  
additional or alternative explanation(s) for the causality  which includes a statement as 
to whether the event was or was not related to the use of the investigational drug.
4.Promptly inform the governing IRB/IEC of the SAE as required b y the IRB/IEC, 
local regulations, and the governing health authorities.
9.4Exposure to Investigational Pr oductduring Pregnancy
Study center personnel must report every  pregnancy  from the time he or she signs the ICF for 
the trial until 30 day safter the last dose of investigational product on 
the Pregnancy  Form as 
soonas possible ( within 24 hours of learning of the pregnancy  tothe SAE/pregnancy fax 
number, ) even if no AE has occurred. Pregnancies in female partners of 
male patients must also be reported. The pregnancy must be followed to term and the 
outcome reported b y completing a follow -up Pregnancy  Form. If, howev er, the pregnancy is 
associated with a SAE (eg, if the mother is hospitalized for hemorrhage), in addition to the 
Pregnancy  Form, a separate SAE Form must be filed as described in Section 
9.3with the 
appropriate serious criterion (eg, hospitalization) indicated.

Allergan Confidential Protocol CGP -MD-01, Amendment 2
569.5ALT or AST Elevations
A post treatment event of ALT or AST ≥ 3xULN is considered an Event of Clinical I nterest.  
Any patient with this lab oratory result after investigational product was taken must have 
repeat testing within 48 to 72 hours to confirm the abnormality .  For this repeat testing, the 
following labs must be drawn: hematology and chemistry  panels, international normalized 
ratio (INR), and a toxicology  screen for acetaminophen. In addition, the investigator will 
perform a complete history  and exam to evaluate for possible liver disease. 
All Events of Clinical I nterestmust be reported to Allergan using the AE of Interest form and 
submitted within 24 hours of the time the Investigator becomes aware of the event. All new 
elements of history , physical exam, diagnostic testing results, and other relevant medical 
reports are to be reported for each event.
If an ALT or AST elevation ≥ 3 x ULN is confirmed and the patient meets any of the 
following criteria, close medical follow -up is required:
Patients with ALT or AST ≥ 3xULN and ≤5 xULN and who are as ymptomatic 
with regard to possible liver disease (ie. No fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever , rash or eosinophilia (> 5%))
Patients with ALT or AST ≥ 3xULN and ≤5 xULN and(total bilirubin
<2 xULN and INR<1.5)
Patients who meet these criteria must be followed clinically  and further medical ev aluation 
will be done per the judgment of the investigator and in conjunction with medical personnel 
at Allergan. The Chemistry panel will be repeated 1 to 2 times per week to follow the course 
of ALT/AST elevation. An extra blood serology  sample mustbe collected and sent to the 
central laboratory  for further diagnostic testing at a later date if needed.
If an ALT or AST elevation ≥ 3 x ULN is confirmed and the patient meets any of the 
following criteria, close medical follow -up is also r equired:
ALT or AST ≥ 3 xULN and the patient is sy mptomatic with the appearance of 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever , rash, or 
eosinophilia (>5%)
ALT or AST ≥ 3 xULN and (total bilirubin >2xULN or INR >1.5)
ALT or AST≥ 5 x ULN 
For these patients, possible etiologies for acute hepatic injury  must be excluded. The 
following laboratory  tests mustbe performed:  anti-hepatitis A IgM, hepatitis B surface 
Allergan Confidential Protocol CGP -MD-01, Amendment 2
57antigen,anti-hepatitis B core IgM, hepatitis C antibody , hepatitis C quantitative RNA  by 
PCR, anti -hepatitis E IgM. An extra serology  blood sample willbe collected and sent to the 
central laboratory  for further diagnostic testing at a later date if needed. The patient must be 
followed clinically and further medical evaluation should be done per the judgment of the 
investigator and in conjunction with medical personnel at Allergan. In general, the Chemistry  
panel should be repeated 1to 2times per w eek to follow the course of ALT/ASTelevation. 
For procedural details on the med ical evaluation of liver disease, please see the Study  
Reference Manual.
The investigator mustcontact the Allergan Medical Monitor to discuss all cases of confirmed 
ALT/AST elevation ≥ 3 xULN. All ALT/ASTelevations must be followed until ALT and 
AST return to <1.5 xULNand there is full clinical resolution
Investigational pr oductmust be discontinued if any of the following criteria are met: 
ALT or AST ≥ 3 xULN and the patient is sy mptomatic with the appearance of 
fatigue, nausea, vomiting, right up per quadrant pain or tenderness, fever , rash, or 
eosinophilia (> 5%)
ALT or AST ≥ 3 xULN and (total bilirubin >2 xULN or INR >1.5)
ALT or AST ≥ 5 xULN for more than 2 weeks
ALT or AST ≥ 8 xULN
The patient may be re-challenged with investigational productonly after consultation with 
the Allergan Medical Monitor . For patients who are not re -challenged with investigational 
product,the patient should be discontinued from the study  and complete the Earl y 
Termination Visit 7 and Safety  Follow-Up Visit 8. Patients should receive appropriate follow-
up as per standard of care.
9.5.1 Potential Hy’ s Law Cases
Sites must report every patient who meets the following potential Hy ’s law criteria if this 
occurs within the time the patient signs the ICF until 30 day s after the last dose of 
investigational product:
ALT or AST ≥ 3xULN AND
Total bilirubin ≥ 2 xULN AND
Alkaline phosphatase < 2 xULN
Allergan Confidential Protocol CGP -MD-01, Amendment 2
58A laboratory  alert for potential Hy ’s laws cases will be in place, and the investigators and 
Allergan will be notified immediately  when the above criteria have been met. Any potential 
Hy’s laws case should be considered an SAE and also reported as an AE of Special Interest. 
Complete both an SAE and AE of Special Interest Form as soon as possible (within 24 hours 
of learnin g of the potential Hy ’s law) and fax it to the SAE fax number . The eCRF pages 
associated with potential Hy ’s law cases must be completed within 7 calendar day s. Every 
effort to determine the cause of the liver abnormalities must be made, and close monitori ng 
should be initiated in conjunction with the Allergan medical monitor and in accordance with 
the FDA “Guidance for Industry :Drug Induced Liver Injury  -Pre-Marketing Clinical 
Evaluation” July  2009.For specific instructions, please refer to the Study  Reference Manual.
9.6Procedures for Unmasking of Investigational Pr oduct
When necessary  for the safet y and proper treatment of the patient, the investigator can 
unmask the patient ’s treatment assignment to determine which treatment has been assigned 
and institute appropriate follow -up care.  When possible, the Allergan Medical Monitor 
should be notified prior to unmasking investigational product .  The investigator must inform 
the Allergan Medical Monitor of the unmasking if there is no notifi cation prior to the
unmasking.
The treatment assignment for the patient can be determined by designated site personnel 
logging into the I WRS system via password protected access.  The reason for breaking the 
code must be recorded in the patient’ s source documents.
10. Administra tive Items
This protocol is to be conducted in accordance with the applicable Good Clinical Practice 
(GCP) regulations and guidelines, eg, the Inte rnational Conference on Harmonis ation(ICH)
Guideline on GCP.
10.1Protection of Human Patients
10.1.1 Compliance with In formed Consent Regulations (US 21 CFR 
Part 50) and Relevant Country Regulations
Written informed consent is to be obtained from each patientprior to any study-related 
activities or procedures in the study , and/or from the patient 's legally authorized 
representative .
Allergan Confidential Protocol CGP -MD-01, Amendment 2
5910.1.2 Compliance With IRBor IEC Regulations
This study  is to be conducted in accordance with IRB regulations (U S 21 CFR Part 56.103) 
or applicable IEC regulations.  The investigator must obtain approval from a properl y 
constituted I RB/IEC prior to initiating the study and re -approval or review at least annually .  
Allergan is to be notified immediately if the responsible I RB/IEC has been disqualified or if 
proceedings leading to disqualification have begun.  Copies of all I RB/IEC correspondence 
with the investigator should be provided to Allergan.
10.1.3 Compliance With Good Clinical Practice
This protocol is to be conducted in accordance with the applicable G CPregulations and 
guidelines.
10.1.4 Compliance With Electr onic Records; Electr onic Signatures 
Regulations (US 21CFR Part 1 1)
This study  is to be conducted in compliance with the regulations on electronic records and 
electronic signature.
10.2Changes to the Pr otocol
The investigator must not implement any  deviation from or changes of the protocol without 
approval b y Allergan and prior review and documented approval/favorable opinion from the 
IRB/IEC of a protocol amendment, except where necessary  to eliminate immediate hazards 
to study patients, or when the changes involve only  logistical or administrative aspects of the 
study (eg, change in monitors, change of telephone numbers).
10.3PatientConfidentiality
A report of the results of this study  may be published or sent to the appropriate healt h 
authorities in any  country in which the study  drug may  ultimatel y be marketed, but the 
patient’s name will not be disclosed in these documents.  The patient's name may  be 
disclosed to the Sponsor of the study , Allergan, or the governing health authoritie s or the 
FDA if they inspect the study  records.  Appropriate precautions will be taken to maintain 
confidentiality  of medical records and personal information.
10.3.1 PatientPrivacy
Written authorization and other documentation in accordance with local privacy r equirements 
(where applicable) is to be obtained from each patientprior to enrollment into the study , 
and/or from the patient 's legally authorized representative in accordance with the applicable 
Allergan Confidential Protocol CGP -MD-01, Amendment 2
60privacy requirements (eg, the Health Insurance Portability  and Accountability  Act Standards 
for Privacy  of Individually Identifiable Health Information (“HIPAA”).
In accordance with HIPAA requirements, additional purposes of this study may include
publishing of anonymous patient data from the study .
10.4Documentation
10.4.1 Source Documents
Source documents may  include a patient's medical records, hospital charts, clinic charts, the 
investigator's patient study files, the eDiary , as well as the results of diagnostic tests such as , 
laboratory  tests and electrocardiograms. Theinvestigator's cop y of the case report forms 
serves as part of the investigator's record of a patient's stud y-related data.
The following information should be entered into the patient's medical record:
Patient’s name.
Patient’s contact information.
The date that the patiententered the stud y, patientnumber, and patient randomizat ion 
[or medication kit] number.
The study  title and/or the protocol number of the study  and the name of Allergan.
A statement that informed consent was obtained (including the date).  A statement that 
written authorization or other local patientprivacy required documentation for this 
study has been obtained (including the date).
Dates of all patient visits.
Patient’s medical history
Information regarding patient’ s diagnosis of migraine headache
All concurrent medications (L ist all prescription and non-prescription medications 
being taken at the time of enrollment.  At each subsequent visit, changes to the list of 
medications should be recorded.)
Occurrence and status of any  adverse events.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
61The date the patient exited the study , and a notation as to whether the patient
completed the study  or reason for discontinuation.
The results of laboratory  tests performed b y the site (eg, resu lts of urine pregnancy  
tests)
Key study variables
Source documentation practices must follow Section 4.0 of I CH E6, Good Clinical Practice: 
Consolidated Guidance and ALCOA, i.e., records must be attributable, l egible, 
contemporaneous, original and accurate.
10.4.2 Case Report Form Completion
The investigator is responsible for ensuring that data are properly  recorded on each patient's 
eCRFand related documents.  An investigator who has signed the protocol signature page 
should personally  sign for the case report forms (as indicated in the case report forms) t o 
ensure that the observations and findings are recorded on the case report forms correctly  and 
completely .  The eCRFsare to be submitted to Allergan in a timel y manner at the completion 
of the study , or as otherwise specified b y Allerganand will be main tained in a central data 
repository .
10.4.3 Study Summary
An investigator's summary  will be provided to Allergan within a short time after the 
completion of the study , or as designated b y Allergan.  A summary is also to be provided to 
the responsible IRB/IEC.
10.4.4 Retention of Documentation
All study related correspondence, patientrecords, consent forms, patientprivacy 
documentation, records of the distribution and use of all investigational products, and copies 
of case report forms should be maintained on file.
For countries falling within the scope of the ICH guidelines, t he sponsor -specific essential 
documents should be retained until at least 2 y ears after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplat ed marketing 
applications in an I CH region or at least 2 y ears have elapsed since the formal 
discontinuation of clinical development of the investigational product.  These documents 
should be retained for a longer period, however , if required b y the applic able regulatory  
requirement(s) or if needed by  the sponsor .
Allergan Confidential Protocol CGP -MD-01, Amendment 2
62In addition, for countries not falling within the scope of the ICH guidelines, local regulatory  
requirements should be followed regarding the retention of clinical study  documentation.
Allergan re quires that it be notified in writing if the investigator wishes to relinquish 
ownership of the data so that mutually  agreed-upon arrangements can be made for transfer of 
ownership to a suitably qualified, responsible person.
10.5Labeling, Pack aging,and Return or Disposal of Investigational 
Products/Treatments
10.5.1 Labeling/Pack aging
Investigational product will be supplied in blister cards and will be labeled with the protocol 
number, storage information, warning language, and instructions to take the ta blets as 
directed. The card will also include the medication number . Immediately  before dispensing 
the blister card, the investigator or designee will write the study  center number , patient’s 
initials and patient number, and date on the blister card.
10.5.2 Clinical Supply Inventory
The investigator must keep an accurate accounting of the number of investigational units 
received from Allergan, dispensed or administered to the patients, the number of units 
returned to the investigator by  the patient(if applicable), and the number of units returned to 
Allergan during and at the completion of the study .  A detailed inventory  must be completed 
for the investigational product .  The investigational product must be dispensed or 
administered only by an appropriatel y qualified person to patient s in the study .  The 
medication is to be used in accordance with the protocol. 
10.5.3 Return or Disposal of Investigational Product s/Treatments
and/or Supplies
All clinical investigational products/treatments and/or supplies will be retu rned to Allergan or 
Allergan designee for destruction.
10.6 Monitoring by the Sponsor
A representative of the sponsor will monitor the study  on a periodic basis.  The determination 
of the extent and nature of monitoring will be based on considerations such as t he objective, 
purpose, design, complexity , blinding, siz e, and endpoints of the study .
Allergan Confidential Protocol CGP -MD-01, Amendment 2
63Authorized representatives of Allergan or regulatory authority representatives will conduct 
on-site visits to review , audit and copy  study-related documents.  These repr esentatives will 
meet with the investigator(s) and appropriate staf f at mutually  convenient times to discuss 
study-related data and questions.
10.7Handling of Biological Specimens 
Urine pregnancy  test kits will be provided by  the central lab; all urine pregna ncy testing will 
be administered on site according to instructions in the central lab manual.  
Samples of blood and urine for evaluation of hematology , blood chemistry , urinalysis, and 
serology will be anal yzed at a centralized clinical laboratory  with certification from a 
recognized accreditation agency  (eg, College of American Pathology  or Clinical Laboratory  
Improvement Amendments certification).
DBS samples obtained from patients in the PK substudy  will be stored at the centralized 
clinical laboratory  until ready  for PK anal yses by Allergan’s Pharmacokinetics and Drug 
Distribution department using a validated method. This laboratory  meets Good L aboratory  
Practice requirements.
All samples will be returned to Allergan or Allergan’s designee for destructi on. Allergan shall 
have full ownership rights to any  biological specimens/samples derived from the study .  For 
additional details regarding handling of biological specimens please refer to the Study  
Reference Manual.
10.8Publications
Allergan as the sponsor , has proprietary  interest in this study . Authorship and manuscript 
composition will reflect joint cooperation between multiple investigators and sites and 
Allergan personnel.  Authorship will be established prior to the writing of the manuscript.  As 
this study involves multiple centers, no individual publications will be allowed prior to 
completion of the final report of the multicenter study  except as agreed with Allergan.
10.9Coordinating Investigator
A signatory Coordinating I nvestigator will be designated pr ior to the writing of the Clinical 
Study Report.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
6411. References
Bigal ME , Dodick DW , Rapoport AM, Silberstein SD , Ma Y, and Yang R,et al. Safety , 
tolerability , and efficacy of TEV-48125 for preventive treatment of high -frequency  episodic 
migraine: a multicentre, randomised, double- blind, placebo -controlled, phase 2b study . 
Lancet Neurol. 2015 Nov;14(1 1):1081-90.
Brandes J L, Saper JR, Diamond M, Couch JR, L ewis DW, Schmitt J, Neto W , Schwabe S, 
Jacobs D. MIGR-002 Study  Group. Topiramate for migraine prevention: a randomized 
controlled trial. JAMA. 2004 Feb 25;291(8):965 -73.
Bretz F, Posch M, Glimm E, Klinglmueller F , Maurer, Rohmey er K. Graphical approaches 
for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests . 
Biometrical Journal. 53 (201 1) 6, 894–913.
ConnorKM,ShapiroRE,DienerHC,LucasS,KostJ,FanX,FeiK,AssaidC, Lines C, Ho
TW.Randomized, controlled trialoftelcagepant for theacutetreatment ofmigraine. 
Neurolog y. 2009 Sep 22;73(12):970-977.
Dodick DW , Goadsby  PJ, Silberstein SD, L ipton RB, Olesen J, and Ashina M . Safety and 
efficacy of ALD403, an antibody  to calcitonin gene -related peptide, for the prevention of 
frequent episodic migraine: a randomised, double- blind, placebo -controlled, exploratory  
phase 2 trial. Lancet Neurol. 2014;13:1 100-7.
Dodick DW , Goadsby  PJ, Spierings EL, Scherer JC, Sweeney  SP, Grayzel DS. Safety and
efficacy of LY2951742, a monoclonal antibody  to calcitonin gene -related peptide, for the 
prevention of migraine: a phase 2, randomised, double- blind, placebo -controlled study .
Lancet Neurol. 2014 Sep;13(9):885-92.
Headache Classification Committee of the International Headache Societ y (IHS). The 
International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 
2013;33(9):629 –808.
Hewitt DJ, Martin V, Lipton RB, Brandes J, Ceesay  P, Gottwald R, et al. Randomized 
controlled study  of telcagepant plus Ibuprofen or acetaminophen in migraine. Headache. 
2011;51:533–543.
Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L , 
Goadsby PJ, Michelson D. Randomized controlled trial of the CGRP  receptor antagonist 
telcagepant for migraine prevention. Neurology . 2014 Sep 9;83(1 1):958-66.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
65Hu XH,Markson LE,LiptonRB,StewartWF,BergerML.Burdenofmigraine inthe 
United States. Arch Intern Med. 1999;159:813 -818.
Katsarava Z, Buse DC, Manack AN, and Lipton RB. Defining the Differences Between 
Episodic Migraine and Chronic Migraine. Curr Pain Headache Rep. 2012:16:86 –92
Li CC, Vermeersch S , Denney WS, Kennedy  WP, Palcza J , and Gipson A. Characterizing the 
PK/PD relationship for inhibition of capsaicin -induced der mal vasodilatation by  MK-3207, 
an oral calcitonin gene related peptide receptor antagonist. Br J Clin Pharmacol.
2014;79;831-7.
LiptonRB,BigalME.Migraine: epidemiolog y,impact,andriskfactorsforprogression. 
Headache. 2005;45(Suppl 1):S3 -S13.
LiptonRB,BigalME, Diamond M, Freitag F , Reed ML , and Stewart WF.Migraine 
prevalence, disease burden, and the need for preventive therap y. Neurology  
2007;68:343 -349.
Olesen J, Bousser MG , Diener HC , Dodick D , First M, Goadsby PJ, et al. New appendix 
criteria open for a broader concept of chronic migraine. Cephalalgia. 2006:26;742 -6.
OlesenJ,Diener H-C, Husstedt IW, GoadsbyPJ,Hall D,Meier U, etal.Calcitoningene-
relatedpeptidereceptorantagonist BIBN 4096 BSfortheacutetreatment ofmigraine.
NEnglJ Med. 2004:350; 1104-1110.
Silberstein SD, Neto W , Schmitt J, Jacobs D. MIGR-001 Study  Group. T opiramate in 
migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61(4):490-5.
Stovner L J, Andree C. Prevalence of headache in Europe: a review for the Eurolight Project. 
J Headache Pain. 2010:11 ;289–299.
Sun H, Dodick DW , Silberstein S, Goadsb y PJ, Reuter U, Ashina M, Saper J, Cady  R, Chon 
Y, Dietrich J, L enz R. Safety  and efficacy of AMG 334 for prevention of episodic migraine: a 
randomised, double -blind, placebo -controlled, phase 2 trial. Lancet Neurol. 2016 
Apr;15(4):382 -90.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
6612. Attachments
12.1 Examination Pr ocedures, Tests, Equipment, and Techniques
12.1.1 International Classification of Headache Disorders , 3rd Edition, 
Beta Version

Allergan Confidential Protocol CGP -MD-01, Amendment 2
67

Allergan Confidential Protocol CGP -MD-01, Amendment 2
68

Allergan Confidential Protocol CGP -MD-01, Amendment 2
69

Allergan Confidential Protocol CGP -MD-01, Amendment 2
70

Allergan Confidential Protocol CGP -MD-01, Amendment 2
71

Allergan Confidential Protocol CGP -MD-01, Amendment 2
72

Allergan Confidential Protocol CGP -MD-01, Amendment 2
73

Allergan Confidential Protocol CGP -MD-01, Amendment 2
74

Allergan Confidential Protocol CGP -MD-01, Amendment 2
75

Allergan Confidential Protocol CGP -MD-01, Amendment 2
76

Allergan Confidential Protocol CGP -MD-01, Amendment 2
77

Allergan Confidential Protocol CGP -MD-01, Amendment 2
78

Allergan Confidential Protocol CGP -MD-01, Amendment 2
79

Allergan Confidential Protocol CGP -MD-01, Amendment 2
80

Allergan Confidential Protocol CGP -MD-01, Amendment 2
8112.2Examples of Pr ohibited Medications
The following medications are prohibited 30 day s prior to screening and throughout the study  
period:
Strong OA TP1B1 inhibitors e.g, Gemfibrozil (Lopid™)
Strong/moderate CYP3A4 
inducersStrong/moderate CYP3A4 
inhibitors
Anti-
Depressants/ 
Anti-AnxietyBarbiturates 
Amobarbital (Am ytal™)
Aprobarbital (Alurate™)
Butalbital (Fiorinal™, 
Fioricet™)
Butabarbital (Busodium™ 
Butisol™)
Mephobarbital (Mebaral™)
Pentobarbital (Nembutal™)
Phenobarbital (Luminal™ 
Solfoton™)
Secobarbital (Seconal™)Nefazodone (Serzone™) 
Anti-SeizureCarbamazepine (Atretol™, 
Carbatrol™, Epitol™, Equetro™, 
Tegretol™)
Oxcarbazepine (T rileptal™)
Phenytoin (Dilantin™, Pheny tek™)
Primidone (My idone™, 
Mysoline™)
Diabetes Pioglitazone (Actos™)
Troglitazone (Rezulin™, Resulin™)
Antiemetic Aprepitant (Emend™)
Anti-
HypertensionDiltiazem (Cardizem™)
Verapamil (Calan™, Calan SR™)
Glucocorticoid 
(Systemic)Betamethasone (Celestone™)
Dexamethasone (Bay cadron™,
DexPak™)
Hydrocortisone (Cortef™)
Methylprednisolone (Medrol™)
Prednisolone (Prelone™)
Prednisone (Deltasone™)
Triamcinolone (Kenalog™)
Allergan Confidential Protocol CGP -MD-01, Amendment 2
82Antibiotics Rifabutin (My cobutin™) 
Rifampicin/ Rifampin (Rifadin™, 
Rifater™, Rimactane™) Erythromycin (Benzamycin™, 
EryTab™)
Clarithromy cin (Biaxin™)
Telithromycin (Ketek™)
Anti-Fungal Fluconazole (Diflucan™, Trican™)
Itraconazole (Sporanox™)
Ketoconazole (Nizoral™)
Anti-HIV Efavirenz (Stocrin™,Sustiva™) 
Nevirapine (V iramune™)Indinavir (Crixivan™)
Nelfinavir (V iracept™) 
Ritonavir (Norvir™)
Saquinavir (Fortovase™, 
Invirase™)
Immune 
SuppressantCyclosporine -Oral/IV only 
(Neoral™,Sandimmune™)
Others St.John’s Wort 
Enzalutamide (Xtandi™)
Modafinil (Provigil™)
Armodafinil (Nuvigil™)Buprenorphine (Cizol™, Subutex™, 
Suboxone™)
Quinine
Drugs with narr ow therapeutic 
margins with potential for  CYP 
drug interactionsWarfarin(Coumadin™)
Digoxin (Digitek™, Lanoxin™, Digox™)
Cisapride ( Prepulsid™, Propulsid™)
Pimozide (Orap™)
Drugs with demonstrated efficacy 
for the prevention of migraineTopiramate (T opamax™)
Valproic acid, sodium valproate, divalproex 
(Depakote™)
Amitripty line (Elavil™)
Nortriptyline (Pamelor™)
Metoprolol (L opressor™, Toprol™)
Atenolol (Tenormin™)
Nadolol (Corgard™)
Propranolol (Inderal™)
Timolol (Apo- Timol™)
Venlafaxine (Effexor™)
Non-pharmacologic headache 
interventions:Acupuncture
TENS (transcutaneous electrical nerve stimulation)
Cranial traction
Nociceptive trigeminal inhibition
Occipital nerve block treatments
Dental splints for headache
Allergan Confidential Protocol CGP -MD-01, Amendment 2
83The following tr eatments ar e prohibited 6 months prior  to screening and thr oughout 
the study period:
BOTOX injections into areas of the head, face, or neck
12.3Classification of Migraine Pr eventive Medications
Below is a list of migraine preventive medications considered ef fective or probably  effective 
sorted by mechanism of action.  Of note, t opiramate and valproic acid derivatives ar e 
considered separate categorie s. A history of inadequate response to 3 or mor e of these 
medications (2 of which have d ifferent mechanisms of action) will exclude the patient from 
the study.
Pharmacologic Category Drug Name
Anticonvulsant Topiramate
Anticonvulsant Valproic acid, sodium valproate, divalproex
Tricyclic Antidepressant Amitripty line
Nortriptyline
Beta-blockers Metoprolol
Atenolol
Nadolol
Propranolol
Timolol
SNRI (serotonin norepinephrine 
reuptake inhibitor)Venlafaxine
Allergan Confidential Protocol CGP -MD-01, Amendment 2
8412.4Glossary of Abbreviations
Term/Abbr eviation Definition
AE adverse event
ALT alanine aminotransferase
ANCOVA analysis of covariance
AST
BIDaspartate aminotransferase
twice dail y
BP blood pressure
CGRP
CIDVcalcitonin gene -related peptide
capsaicin-induced dermal vasodilatation
CRF case report form
C-SSRS Columbia -Suicide Severity  Rating Scale
CYP3A4 cytochrome P450 3A4
DBS dry blood spot
ECG electrocardiogram
eCRF
eTabletelectronic case report form
electronic tablet
EQ-5D-5L European Quality  of Life – 5-Dimensional – 5- Level 
GCP Good Clinical Practices
HIPAA Health Insurance Portability  and Accountability  Act
HIT-6 Headache Impact T est
ICH International Conference on Harmonisation
ICHD-3 beta International Classification of Headache Disorders criteria, 3rd
edition (beta version, 2013)
IEC Independent Ethics Committee
IgM
INRimmunoglobulin M
coagulation parameters
IRB Institutional Review Board
IV intravenous
IWRS interactive web response sy stem
MI
MMRMmultiple imputation
mixed-effects model for repeatedmeasures
NSAID
PGICnonsteroidal anti- inflammatory  drug
Patient Global I mpression of Change
PR
QDpain relief
once daily
Allergan Confidential Protocol CGP -MD-01, Amendment 2
85QTc QT interval corrected for heart rate
QTcF QT interval corrected for heart rate using the Fridericia formula 
(QTcF = QT/(RR)⅓)
PK pharmacokinetic
SAE serious adverse event
SAP statistical analy sis plan
ULN
WPAI-SHPupper limit of normal
Work Productivity  and Activities I mpairment -Specific Health 
Problem
12.5Protocol Amendment 1 Summary
Title:  APhase 2/3, Multicenter , Randomized, Double -Blind, Placebo -Controlled, Parallel-
Group Study  To Evaluate The Efficacy , Safety, And Tolerability Of Multiple Dosing 
Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Protocol CGP -MD-01
Date of Amendme nt:  11Nov 2016
Amendment Summary
This amendment includes changes made to Protocol CGP -MD-01 (09 May 2016).The 
protocol was amended to: 1) update contact information; 2) correct or rephrase inaccurate
text; 3) update the Schedule of visits and procedures; 4) exclude patients who have used 
injectable monoclonal antibodies for CGRP; 5) modify  exclusion criteria #21 and #24; 6) 
clarify use of SSRI s and SNRI s; 7) clarify  childbearing potential, acceptable contraception, 
and male participationrequirements; 8) clarify  the timing of the PK sampl ing;9) exclude 
patients who use benzodiazepines ;10) reorder the secondary  efficacy variables for the EU; 
11) resort all the additional ef ficacy variables and the Health Outcomes V ariables into 2 new 
sections;12)make instructions for the management of patients with ALT or AST  elevations 
obligatory ;and 13) clarify various study  activities.
Following is a summary  of content -oriented changes that were made to each section of the 
protocol, and a brief rationale for these changes.  Minor editorial and document formatting 
revisions have not been summarized.
Allergan Confidential Protocol CGP -MD-01, Amendment 2
86Section Revision Rationale
Protocol T itle Page Revised the name of the US Agent from Allergan 
(North America ) to Allergan Sales, LLC
Added the emergency contact number: +1-866-
438-8820
 
Removed the contact information for the Medical 
Monitor, and inserted: Refer to the Study 
Contacts Page
Added the “Protocol Amendment 1 Date” to the 
title pageThe name of Allergan 
in the US has changed
To remove need to 
consult the study 
contacts page for this 
information
The number has 
changed
To preclude the need 
for amendment should 
the contact info 
change
To reflect the 
approval date of 
Amendment 1
Protocol Summary , 
Response MeasuresReplaced acute medication use with triptan use . 
Corrected the text relating to the name of the
measure: Patient Satisfaction with Study 
Medication for Migraine Prevention .(in this 
section and throughout the protocol)For accuracy
To use the correct 
name of the measure 
Protocol Summary, 
General Statistical 
MethodsCorrected the name of the MMRM: mixed -effects 
model for reportedrepeatedmeasures (in this 
section and elsewhere in the protocol) .
Reordered the secondary efficacy variables for the 
European UnionTo use the correct 
name of the model
For accuracy
   
 
 
  
 
 
   
 
  
  
 
 
  

Allergan Confidential Protocol CGP -MD-01, Amendment 2
87Section Revision Rationale
 
  
 
 
 
 
 
 
  
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
88Section Revision Rationale
Section 1.2, Overview 
of AGN-241689 
AGN-241689For accuracy
Section 3.2 Efficacy 
AssessmentsDeleted the full list of primary, secondary, and 
additional efficacy parameters (for the US and 
EU), and  added text regarding how assessments 
will be collected: Efficacy assessments will be 
based on information recorded by the patient.  An 
eDiary will be used daily at home to collect data 
on headache duration, headache characteristics, 
symptoms, and acute medication use, which will 
be collectively applied to define migraine, 
probable migraine, and headache days per the 
criteria listed in Sections  
 
 
 To eliminate 
repetition of 
information already 
stated elsewhere 
(Section 7.2), and to 
describe the mode of 
data collection
  
 
 
Section 3.5 Drug Data 
Safety Monitoring 
BoardChanged the name of the Drug Safety Monitoring 
Board to DataSafety Monitoring BoardFor accuracy
Section 4.3 Exclusion 
CriteriaAdded text to criterion #8: ( barbiturates are 
excluded during the baseline period and for the 
duration of the study [see Section 12.2 Examples 
of Prohibited Medications] ).
 
 
 
 
 
#24  
 
 
 
 For clarity
To allow patients with 
reversions to be 
included
To exclude patients 
who have used 
injectable monoclonal 
antibodies for the 
CGRP pathway
Section 4.4.1 
Permissible 
Medications/TreatmentsInserted text regarding use of SSRIs and SNRIs: 
Selective serotonin reuptake inhibitors (SSRI) or 
serotonin norepinephrine reuptake inhibitors 
(SNRI) wi ll be permitted provided that treatment To allow for patient 
use of stable -dose (at 
least 60 days prior to 
screening) SSRIs and 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
89Section Revision Rationale
is stable for at least 60 days prior to screening 
(Visit 1) and continues without change in dose 
throughout the study.SNRIs.
Section 4.4.3 Definition 
of Females of (Non- ) 
Childbearing Potential 
and/or Acceptable 
Contraceptive MethodsAdjusted text that defines childbearing potential, 
acceptable contraception, and male participant 
requirements: For purposes of this study, females 
will be considered of childbearing potential unless 
they are naturally postmenopausal (ie, no menses 
for 2 years) or permanently sterilized (ie, bilateral 
tubal ligation , bilateral salpingectomy, bilateral 
oophorectomy   or hysterectomy).  
For women of chi ldbearing potential who may 
participate in the study, the following methods of 
contraception, if properly used, are generally 
considered reliable: hormonal contraceptives (ie, 
oral, patch, vaginal ring,   injection, implant), male 
condom with intravaginal s permicide, diaphragm 
or cervical cap with spermicide, vaginal 
contraceptive ring, intrauterine device, surgical 
sterilization (bilateral tubal ligation, bilateral 
salpingectomy), vasectomized partner, or sexual 
abstinence.
Male participants must also refra in from donating 
sperm during the course of the study.For clarity regarding 
acceptable means of 
contraception , and to 
forbid sperm donation 
during the study.
 
 
  
 
 
 
 
 
  
  
 
 
  
 
 
 
  
 
  
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
90Section Revision Rationale
.  
 
 
  
 
 
 
6.3 Future Biomedical 
ResearchRevised text to clarify possible uses of samples 
and to clarify destruction of by- products of the 
samples from patients who withdraw consent.For clarity
Table 6–1 Clinical 
Laboratory ParametersAdded benzodiazepines to the list of urine drug 
screen parametersTo accurately reflect 
the urine drug screens 
being conducted
   
 
 
 
 
 
  
 
 
 
  
   
Section 8.9 Withdrawal 
CriteriaThe withdrawal criteria have been restated: 
Women who become pregnant (Section 9.4) and 
patients  who meet investigational product 
discontinuation criteria experience treatment -
emergent AEs related to abnormal liver function 
tests (Section 9.5) and advised not to be re -
challenged willbe withdrawn from the study and 
should refrain from taking investigational 
product. The patient should return to the clinic for 
early termination procedures (Visit 7) and the 
Safety Follow -up Visit 8. For clarity
Section 8.10 
Withdrawal from 
Future Biomedical 
ResearchText regarding destruction of patient’s samples 
has been replaced with: A patient who initially 
consents can withdraw that consent at any time 
and have his or her sample destroyed, including 
any by-products of the sample whenever possib le. 
If a patient withdraws consent, their physical For accuracy

Allergan Confidential Protocol CGP -MD-01, Amendment 2
91Section Revision Rationale
sample will be destroyed and no new health 
information identifying the patient will be 
gathered after that date. However, once the 
genetic data is anonymized and placed into the 
biorepository database afte r study database lock, 
the information cannot be withdrawn.
Section 9.5 ALT or 
AST ElevationsThroughout this section, the instructions for 
patients with ALT or AST  ≥ 3xULN, have been 
made obligatory. All previous instructions that 
indicated “should” have been replaced with 
“must” or “will”, and additional instructions have 
been added to paragraphs 4, 6, and 9: 
An extra blood serology sample should must be 
collected and sent to the central laboratory for 
further diagnostic testing at a late r date if needed.
An extraserologyblood sample should willbe 
collected and sent to the central laboratory for 
further diagnostic testing at a later date if needed.
For patients that are not re -challenged with 
investigational product the patient should b e 
discontinued from the study and complete the 
Early Termination Visit 7 and Safety Follow -Up 
Visit 8. Patients should receive appropriate 
follow-up as per standard of care.For patient safety
Section 9.6 Procedures 
for Unmasking of 
Investigational ProductText has been revised to make notification of the 
sponsor obligatory when there was no prior 
notification of unmaskingFor clarity
Section 12.2 Examples 
of Prohibited 
MedicationsArmodafinil (NuvigilTM) has been added to the 
“Others” rowFor accuracy
Section 12.3 
Classification of 
Migraine Preventive 
MedicationsText has been added to Paragraph 1 to clarify that 
the list refers to medications that are effective or 
probably effective for prevention of migraine. 
Explanatory footnotes have been deleted.For accuracy
12.6Protocol Amendment 2 Summary
Title:  APhase 2/3, Multicenter , Randomized, Double -Blind, Placebo -Controlled, Parallel-
Group Study  To Evaluate The Efficacy , Safety, And Tolerability Of Multiple Dosing 
Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Allergan Confidential Protocol CGP -MD-01, Amendment 2
92Protocol CGP -MD-01
Date of Amendment 2:  11Sep 2017
Amendment Summary
This amendment includes changes made to original Protocol CGP- MD-01 (09 May  2016)as 
amended with Amendment 1 (1 1 Nov 2016). The protocol was amended to: 1) allow 
participation of patients with history  of hemiplegic migraine ; 2) revise the primary  and 
secondary  efficacy endpoints for the US and EU ; 3) revise the multiple comparisons 
procedure ; 4) updatethe sample size calculation ; 5) define “one month” for the efficacy 
analysis; 6) revise the additional ef ficacy variables for the US and EU ; and 7) clarify  the 
section on earl y discontinuation of patients.
Following is a summary  of content -oriented changes that were made to each section of the 
protocol, and a brief rationale for these changes.  In this summary, added text is shown
underlined, and deleted text is shown as strikethrough. Minor editorial and document 
formatting revisions have not been summarized.
Section Revision Rationale
Protocol Summary , 
Clinical Hypotheses , 
and Section 2.2 
Clinical HypothesesRewrite the Clinical Hypotheses :In individuals with 
episodic migraine, at least one of thefollowing 
doses (10- mg QD,  30 -mg QD, 30 -mg BID, 60 -mg 
QD, and 60 -mg BID) doseactive treatment arm, 60 
mg QD or 60 mg BIDis superior to placebo as 
measured by the change from baseline in mean
monthly number of migraine/probable migraine 
(MPM)headache days acrossthe12-week treatment 
period in the last 28 days of the treatment per iod 
ending with week 12 .Per discussion 
with regulatory 
authority
Protocol Summary, 
Study Population 
Characteristics, Key 
Exclusion Criteria , 
Section 4.3 (criterion 
#2)Remove the exclusion of participants with history of 
hemiplegic migraine: 
Has a history of migraine with accompanied by diplopia 
or decreased level of consciousness or, hemiplegic 
migraine, and retinal migraine as defined by ICHD -3 beta 
version, 2013 Per discussion 
with regulatory 
authority
Protocol Summary, 
Response MeasuresRevise the e fficacy measure for triptan use: 
Frequency of migraine or probable migraine 
headache days, headache days, and triptan use acute 
medication use daysPer discussion 
with regulatory 
authority
Protocol Summa ry, 
General Statistical 
Methods,and Section Revise the primary efficacy endpoint : 
The primary efficacy endpoint is the change from 
baseline in mean monthly MPM headache days 
across the 12-week treatment period the frequency Per discussion 
with regulatory 
authority
Allergan Confidential Protocol CGP -MD-01, Amendment 2
93Section Revision Rationale
7.3.1 Primary Efficacy 
Analysesof migraine/probable migraine headache days per 4 
weeks, the primary measurement time is the 28 days 
ending with diary week 12, and the primary analysis 
is on the change from baseline .  Comparisons 
between each dose group and placebo will be done 
by a mixed- effects model for repeated m easures 
(MMRM) of the change from baseline.  The 
statistical model will include treatment group, visit 
and treatment group by visit interaction as 
categorical fixed effects.  It will also include the 
baseline score and baseline -by-visit interaction as 
covariates.  Pairwise contrasts in the MMRM model 
will be used to make the pairwise c omparisons of 
dose to placebo. A sensitivity analysis will be 
performed on the primary endpoint to assess the 
robustness of the MMRM analysis to possible 
violation of the miss ing-at-random (MAR) 
assumption.  The sensitivity analysis will be done 
using a pattern -mixture model (PMM), under which 
data could be missing -not-at-random (MNAR), with 
repeated analyses combined via the multiple 
imputation procedure (MI). An additional 
sensitivity, multiple imputation in conjunction with 
robust regression, will be performed in case of non -
normality for the primary efficacy endpoint.      
Protocol Summary, 
General Statistical 
Methods Revise the secondary efficacy endpoints: 
Secondary efficacy endpoints will be analyzed 
separately for the United States (US) and Europe 
(EU) submissions. Secondary efficacy endpoints for 
the US include: (1) Change from baseline in mean 
monthly headache da ys across the 12-week 
treatment period Change from baseline in number of 
headache days to the last 28 days of the treatment 
period ending with week 12 ; (2) Proportion of 
patients with at least a 50% reduction in mean 
monthly MPM days across the 12-week treatment 
period migraine/probable migraine headache days in 
the last 28 days of the treatment period ending with 
week 12; (3) Change from baseline in mean monthly 
acute medication use days across the 12-week 
treatment period Change from baseline in the 
activities of daily living (ADL) domain score of the 
ACM-I (Assessment of Chronic Migraine Impact)  
at week 12; (4) Proportion of patients “satisfied” or 
“extremely satisfied” with study medication for 
migraine prevention at week 12. Secondary efficacy 
endpoints for the EU include: (1) Change from 
baseline in number of headache days to the last 28 Per discussion 
with regulatory 
authority
Allergan Confidential Protocol CGP -MD-01, Amendment 2
94Section Revision Rationale
days of the treatment period ending with week 12; 
(2)Proportion of patients with at least a 50% 
reduction in migraine/probable migraine headache 
days per 28 day period at the end of the 12 week 
treatment period; (3) Change from baseline in 
number of triptan use days to the last 28 days of the 
treatment period ending with week 12; (4) Change 
from baseline in the HIT -6 total score (Headache 
Impact Test)  at week 12.
Protocol Summary, 
General Statistical 
MethodsRevise the multiple comparisons procedure: 
The overall type I error rate for multiple 
comparisons across active treatment doses and the 
primary and four secondary efficacy parameters will 
be controlled at the 0.05 level using a graphical 
approach by Bretz et al ( 20112009).  The weighting 
strategy of the multiple comparisons is designed to 
allocate initial alpha equally to the QD and BID 
dose regimen s. Within each dosing regimen, 
individual AGN-241689 doses will be tested in a 
hierarchical order from high to low dose, i.e. for 
primary efficacy endpoint, low dose can be tested 
only if high dose comparison shows statistical 
significance. In addition, for a giv en dose 
comparisonversus placebo, the strategy has the 
primary endpoint as gatekeeper to the secondary 
endpoints so that secondary endpoints can be tested 
only if primary hypothesis of the corresponding 
dose comparison reaches statistical significance.   
allocates ¼ weight to each of 30 mg QD, 30 mg 
BID, 60 mg QD and 60 mg BID comparisons versus 
placebo for the primary hypothesis.  If any of those 
comparisons is rejected, 20% of the corresponding 
weight will be propagated to test 10 mg QD versus 
placebo for the primary hypothesis and 80% of the 
weight will be propagated to test the first secondary 
hypotheses in the corresponding dose versus 
placebo. Then for the comparison of each dose 
versus placebo, 100% of the weight will be 
propagated sequentially for t he remaining secondary 
endpoints. Finally, if for one of the doses efficacy 
can be shown for primary and all the secondary 
endpoints, the associated weight is passed on to 
other doses. This weighting strategy implies that the 
10 mg QD versus placebo compar ison can only be 
tested if at least one of the 30 mg QD, 30 mg BID, 
60 mg QD and 60 mg BID versus placebo 
comparisons for the primary hypothesis is rejected 
and a small amount of weight is to be allocated to 
the 10 mg QD versus placebo comparison, since it is Per discussion 
with regulatory 
authority
Allergan Confidential Protocol CGP -MD-01, Amendment 2
95Section Revision Rationale
selected as a likely suboptimal dose.  Similarly, 
under this strategy, no secondary hypothesis can be 
rejected until a primary hypothesis of the 
corresponding dose comparison is rejected.  The 
primary endpoint will serve as the gatekeeper for the 
secondary endpoints. Weighted Simes Bonferroni 
tests will be used for testing the hypotheses. within 
each endpoint as the associated test statistics are 
positively correlated, and a Bonferroni mixture will 
be used to combine test results across different 
endpoints. A complete decision -flow graph and 
details of the graphical multiple comparison 
procedure will be presented in the statistical analysis 
plan of this study.
Protocol Summary, 
General Statistical 
Methods, Sample Size 
Calculation ; and 
Section 7.7Revise the Sample Size Calculation: 
The assumptions and corresponding power 
assessments for the primary efficacy endpoint are 
shown in the table below(Note: the revised table is 
not included here) .The treatment difference 
assumption is based on results from other episodic 
migraine prevention studies: the placebo -adjusted 
reduction in monthly migraine days ranged from 1.1 
to 2 days (topiramate [ Silberstein et al. 2004 and 
Brandes et al. 2004 ], telcagepant [ Ho et al., 2014], 
and CGRP monoclonal antibodies Ph2 studies 
[Dodick et al., 2014; Dodick et al., 2014; Bigal et 
al., 2015; Sun et al 2016 ], and their Ph3 studies 
results reported from American Headache Society & 
American Academy of Neuroscience 2017 ). 
Common stan dard deviation is estimated based on 
blinded interim data assessments of this study. 
Power is calculated via 10,000 simulations based on 
multiplicity adjustment.
The following table displays the power calculations 
for treatment comparisons of 30 mg or 60 m g QD 
versus placebo and 30 mg or 60 mg BID versus 
placebo, respectively. The differences between 
treatment groups in the mean number of 
migraine/probable migraine headache days change 
from baseline at the primary timepoint (Week 12) is 
assumed to be 1.5 fo r the comparison of 30 mg or 
60 mg QD versus placebo (assumed equally 
effective for 30 mg QD and 60 mg QD), and be 1.75 
for the comparison of 30 mg or 60 mg BID versus 
placebo (assumed equally effective for 30 mg BID 
and 60 mg BID). With the allocated ¼ we ight, each 
of the hypotheses will be tested at alpha level of Updated to reflect 
revised primary 
endpoint and 
multiplicity 
strategy
Allergan Confidential Protocol CGP -MD-01, Amendment 2
96Section Revision Rationale
0.0125 using the Bonferroni approach for power 
calculation. This is a more conservative power 
assessment compared to the weighted Simes test 
used in the final analysis. The statistical power 
calculations are focused on doses of 30 mg QD, 30 
mg BID, 60 mg QD and 60 mg BID, because the 10 
mg QD is considered to likely be a suboptimal dose 
and is only tested if at least one of the 4 doses 
comparison is significant. For critical alpha level 
0.0125, the powers are displayed based on a 
standard deviation estimate of 4.0.
Section 6.1.1.4 Acute 
Medication Use Day 
and Triptan Use DayDescribe the allowed medications for headache 
pain: 
The allowed medications include the following 
categories of drugs: triptans, ergots, opioids, 
analgesics (including acetaminophen), NSAIDs 
(including aspirin), and antiemetics.For clarity
 
  
 
 
 
 
 
 
Section 7.2 Collection 
and Derivation of 
Primary and 
Secondary Efficacy 
AssessmentsRevise section to define “one month”. For analysis 
purposes, four weeks (28 days) will be considered 
as one month.For clarity
Section 7.2.1 Primary 
Efficacy VariableRevise the primary efficacy variable: The primary 
efficacy variable is the change from baseline in 
mean monthly MPM headache days across the 12-
week treatment period. the frequency of 
migraine/probable migraine headache days to the 
28-day period ending with Week 12 (ie, Day 57 to 
Day 84 inclusive, relative to the day 1 treatment 
start).Per discussion 
with regulatory 
authority

Allergan Confidential Protocol CGP -MD-01, Amendment 2
97Section Revision Rationale
Section 7.2.2
Secondary Efficacy 
Variables for the 
United StatesRevise the secondary efficacy variables: 
The 34secondary effi cacy variables for the US 
include:
Change from baseline in mean monthly number 
ofheadache days across the 12-week treatment 
periodto the last 28 days of the treatment period 
ending with week 12 .
Proportion of patients with at least a 50% 
reduction in mean monthly migraine/probable 
migraine headache days across the12-week 
treatment periodin the last 28 days of the 
treatment period ending with week 12 .
Change from baseline in mean monthly acute 
medication use days the activities of daily living 
(ADL) domain score of the ACM -I (Assessment 
of Chronic Migraine Impact)  at week 12
Proportion of patients “satisfied” or “extremely 
satisfied” with study medication for  migraine 
prevention at week 12.Per discussion 
with regulatory 
authority
  
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
98Section
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
99Section Revision Rationale
 
 
.
Section 7.3.2 
Secondary Efficacy 
AnalysesRevise this section: 
The secondary efficacy variables are identified in 
rank order for the US and EU, respectively, in 
Sections7.2.2 and 7.2.3.  Tocontrol the type 1 error 
rate for multiple secondary endpoints, a gatekeeping 
approach will be used for these secondary variables 
at the primary visit (week 12) according to the rank 
order specified.  
Specifically, t The overall type I error rate for 
multiple comparisons across active treatment doses 
and the primary and secondary efficacy parameters 
will be controlled at the 0.05 level using a graphical 
approach by Bretz et al. (2011) .  The weighting 
strategy of the multiple comparisons is designed to 
allocate initial alpha equally to the QD and BID 
dose regimen. Within QD or BID dose regimen, 
AGN-241689doses will be tested in a hierarchical 
order from high to low dose, i.e. for primary 
efficacy endpoint, low dose can be tested only if 
high dose compariso n shows statistical significance. 
In addition, for a given dose comparing versus 
placebo, the strategy has the primary endpoint as 
gatekeeper to the secondary endpoints so that 
secondary endpoints can be tested only if primary 
hypothesis of the correspondi ng dose comparison 
reaches statistical significance. allocates ¼ weight to 
each of 30 mg QD, 30 mg BID, 60 mg QD and 60 
mg BID comparisons versus placebo for the primary 
hypothesis.  If any of those comparisons is rejected, 
20% of the corresponding weight w ill be propagated 
to test 10 mg QD versus placebo for the primary 
hypothesis and 80% of the weight will be 
propagated to test the first secondary hypotheses in 
the corresponding dose versus placebo. Then for the 
comparison of each dose versus placebo, 100% of 
the weight will be propagated sequentially for the 
remaining secondary endpoints. Finally, if for one 
of the doses efficacy can be shown for primary and 
all the secondary endpoints, the associated weight is 
passed on to other doses. This weighting stra tegy 
implies that the 10 mg QD versus placebo 
comparison can only be tested if at least one of the 
30 mg QD, 30 mg BID, 60 mg QD and 60 mg BID 

Allergan Confidential Protocol CGP -MD-01, Amendment 2
100Section Revision Rationale
versus placebo comparisons for the primary 
hypothesis is rejected and a small amount of weight 
is to be allocated to the 10 mg QD versus placebo 
comparison, since it is selected as a likely 
suboptimal dose.  Similarly, under this strategy, no 
secondary hypothesis can be rejected until a primary 
hypothesis of the corresponding dose comparison is 
rejected.  The primary endpoint will serve as the 
gatekeeper for the secondary endpoints. Weighted 
Simes Bonferroni tests will be used for testing the 
hypotheses within each endpoint as the associated 
test statistics are positively correlated, and a 
Bonferroni mixture will be used to combine test 
results across different endpoints. A complete 
decision-flow graph and details of the graphical 
multiple comparison pro cedure will be presented in 
the statistical analysis plan of this study.
 
  
 
 
 
 
 
 
.
Section 8.8 Early 
Discontinuation of 
PatientsRevise the last paragraph of this section: 
Patients may voluntarily withdraw from the study at 
any time. Notification of early patient 
discontinuation from the study and the reason for 
discontinuation will be clearly documented on the 
appropriate case report form. All randomized 
patients who premat urely discontinue from the 
study, regardless of cause, should be seen for a final 
studyassessment s. Thefinal assessment swill be 
defined as completion of the evaluations scheduled 
for Visit 7/Early Termination and Visit 8 Safety 
Follow-up, 4 weeks post the last dose of IP.For clarity
Section 11.References Additional references added. To support revised 
sample size 
calculation
